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Chapter 1 
Anti-IL2 Receptor monoclonal antibodies in organ transplantation 
This chapter is a modified versioll of a revielV all this subject, published as "Anti-
IL2Receptor mOlloc/ollal antibodies ill orgall trallsplalltatioll." ill Developments ill 
Nephrology - Leidell; Boer/wave course 1995. 
1.0 Introduction 
Results of solid organ transplantation have improved steadily over the last 
decades. However, both acute and chronic rejections are still frequently found. 
Detailed single center studies have shown that the presence or absence of acute 
rejection episodes is one of the most powerful predictors of chronic rejection 
and late graft failure' 23. In order to reduce the incidence of acute rejection in 
the immediate postoperative period and to promote long·term 
hyporesponsiveness to donor allo-antigens, the use of induction therapy with 
anti T-Iymphocyte antibodies has been widely promoted'. Especially OKT3, a 
murine monoclonal anti-CD3 antibody, has been used for this reason in some 
regimens with the additional advantage of delaying the requirement for 
cyclosporin, thereby reducing the risk of nephrotoxicity' '. The use of OKT3, 
however, has several limitations7 : first dose reactions may be life-threatening' 
(cytokine release syndrome' '0), the procoagulant-effect may lead to early 
graft loss ", and infections 12 '3 and neoplasms 14 may complicate the 
clinical course as a result of excessive immunosuppression. Polyclonal anti T-
lymphocyte antibody preparations additionally have the problem of batch-to-
batch variability and the risk of serum sickness 16. 
To avoid the drawbacks of aselective immunosuppression of anti-pan T-cell 
preparations, monoclonal antibodies against specific T-cell activation 
determinants have been developed". Using monoclonal antibodies T-cell 
responsiveness might be manipulated in an attempt to achieve donor-specific 
tolerance17 • Antibodies directed against specific molecules that are only 
expressed after antigenic stimulation and involved in the early steps toward 
clonal expansion of alia reactive precursors will only interfere with the resulting 
antigen-committed cells. An example are the anti Interleukin-2Receptor 
monoclonal antibodies". 
1.1 Interleukin-2 and the Interleukin-2Receptor 
In the seventies it was established that T-cells are the source of a substance 
with mitogenic activity, sustaining long term T-cell growth 19• The term "T-cell 
growth factor,,20 was changed into interleukin-2, according to the international 
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Iymphokine nomenclatura, when the molecular properties of IL-2 were 
defined" 22 and cDNA clones were isolated and sequenced". 
IL-2 acts on several cells of the immune system, such as B lymphocytes, 
macrophages and natural killer cells". It has a pivotal role in the antigen-
specific clonal proliferation of T-Iymphocytes, where it stimulates growth in an 
autocrine and paracrine fashion via interaction with IL-2Receptors". These IL-
2Rs have all the characteristics of true cytokine receptor molecules, including 
high affinity, saturability, ligand specificity and target cell specificity. The IL-2R 
originally was thought to consist of an a(p55)- and B(p75)-chain'6 ". 
Recently an additional molecule was found, the V(p64)-chain", associated with 
the B-chain, and neccessary for the formation of functional intermediate and 
high affinity IL-2Rs'9 30. A mutant T cell line that has lost expression of the 
gamma chain but retains the alfa and beta chains has been shown to have also 
lost the ability to respond to IL-231 • 
Although the low-affinity IL-2Ra chain is able to bind IL-2, this proces is not 
functionally followed by signal transduction". In contrast, the intermediate-
and high-affinity IL-2R both can internalize IL-2. The large cytoplasmic region of 
the IL-2RB chain, consisting of 286 amino acids, is the most likely candidate 
involved in driving the IL-2 dependent signal pathways". 
The in vitro proliferative response of resting lymphocytes to IL-2 can be divided 
into two phases": in the first phase concentrations of IL-2 high enough to bind 
intermediate affinity receptors are required. Cells respond by expressing IL-2Ra 
de novo and by increasing IL-2RB chain expression. After 16 hours significant 
numbers of high-affinity receptors are expressed and subsequent proliferation 
can be maintained by low-dose IL-2 (sufficient to bind high affinity receptors but 
not enough to appreciably bind intermediate affinity receptors). Upon antigen or 
mitogen stimulation the a chain expression is highly upregulated (30-100 fold), 
whereas the B chain induction is only 3-4 fold increased". Three days after 
polyclonallymphocyte stimulation maximal IL-2R levels are measured. Thereafter 
the level of IL-2R declines progressively, proliferation eventually ceases while 
most cells return in the resting phase of the cell cycle (Go or early G,) by 12 to 
14 days after initiation of the culture". This experiment shows that IL-2R 
expression is transient. In vivo studies using polymerase chain reaction to 
examine IL-2 gene transcription within fine needle aspiration biopsies from renal 
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allograft recipients with an acute rejection,taken on a daily basis, also showed 
transient IL-2 gene expression37 • More support for an important role of IL-2 in 
allograft rejection was obtained from studies where IL-2R positive cells were 
found to be present in rejecting grafts" 39 40, and from a study that showed 
strong binding of radio-labeled IL-2 to high-affinity IL-2Receptors in acute 
rejection 41 . 
1.2 Anti IL-2R mAb in animal models. 
In 1982 a murine IgG" monoclonal antibody, termed anti-Tac, was found to 
bind to the IL-2R a chain and to inhibit IL-2 induced T-cell proliferation42 • 
Blockade of the a or the B chain blocked the high-affinity IL-2R and inhibited 
internalization of the ligand IL-243 • Because high-affinity IL-2R are expressed 
solely by activated T-cells and not by resting T-cells, antibodies against IL-2R 
have been used to achieve a selective immunosuppression in allograft recipients. 
As these anti IL-2R monoclonals do not lyse or activate target cells no toxic 
syndrome is likely to occur. 
In 1985 Kirkman et al44 were the first to demonstrate increased heart and skin 
allograft survival in anti IL-2R mAb (M7/20)45 treated mice, thereby clearly 
emphasizing the role of the IL-2R in the mechanism of graft rejection. In addition 
to preventing rejection they were also able to reverse ongoing rejection with 
M7/20. 
Likewise, the murine anti IL-2R mAb ART18 was found to prolong allograft 
survival and abrogate acute rejection in a rat cardiac allograft model4• 47. 
Using IL-2R targeted therapy in the rejecting host, donor-specific T-suppressor 
cells were thought to be spared, possibly because this subset of T-cells would 
not express IL-2R during early rejection 4B • Transfer of spleen cells from ART-18 
treated hosts into untreated syngeneic animals prolonged graft survival, 
supposedly as a result of these T-suppressor cells, that inhibit the effector 
function of host cells49 • Such donor-specific suppressor cells were also found 
in studies with the anti IL-2R mAb T069'o. Anti IL-2R mAbs have further been 
tested in pancreatic islet", kidney" and neural" allograft transplantation in 
several rodent models, repetitively showing prolonged allograft survival in the 
treated animals. Some authors claim to find a synergistic effect in combining 
anti IL-2R monoclonals and cyclosporin64 • This is explained by the fact that 
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cyclosporin acts at a proximal phase of the immune activation, whereas anti IL-
2R monoclonals target antigen activated cells already generated". 
Not all mAbs directed against the IL-2R are equally effective. A comparison of 
the functional potential of six mAbs directed against the mouse IL-2R p55 unit 
resulted in identification of several epitope clusters'6. The differences in 
epitope~recognition may have important clinical consequences67 68. 
1.3 Anti IL-2R mAb in humans. 
Shortly after the publication of the results of studies with anti-IL-2R mAb in 
animal models, clinical studies in humans were published. The group from 
Nantes, France, used 33B3.1, a rat IgG2a mAb to prevent rejection after kidney 
transplantation. In a prospective trial 100 consecutive recipients of primary 
cadaveric renal allografts were randomized for prophylactic treatment with 
33B3.1 or A TG (Anti Thymocyte Globuline) for the first 2 weeks after 
transplantation". Cyclosporin was started at the end of these 2 weeks. The 
clinical tolerance of 33B3.1 appeared to be good, in contrast to ATG 
administration, which in 32% of the cases had to be interrupted for reasons of 
clinical intolerance. During the 14 day treatment period 6 rejections occurred in 
the 33B3.1 group, compared to only 1 in the ATG-group. The rejection-
incidence at 3 months was nearly identical in both groups (31 % vs 26% in the 
ATG-group), whereas infections were more frequent in the ATG-group. Similar 
results were obtained with 33B3.1 as prophylactic treatment after a second 
kidney transplantation'o. The same group published a third study", in 
combined kidney-pancreas transplantation, where also a higher rejection-
incidence was found in the 33B3. 1-group compared to a control group of ATG-
treated patients. 
Kirkman et al. 62 (Boston, USA) performed an open-labelled randomized trial 
with anti-Tac in primary renal allograft recipients. Transplanted patients received 
either anti-Tac for the first 10 days together with low dose cyclosporine, 
azathioprine and prednisone, or triple drug treatment only. The anti-Tac treated 
group had a significantly longer time to the first rejection-episode, but the 
overall number of rejection-episodes was not significantly reduced. During the 
prophylactic treatment period in the anti-Tac group 5 rejections occurred. 
Infectious complications were evenly distributed. During the first ten days, the 
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percentage of peripheral blood T cells expressing IL-2R was not different 
between the anti-Tac treated and the control group6'. This was in contrast to 
the Nantes study in which the IL-2R positive cells remained almost undetectable 
during administration of 33B3.1. 
In a randomized study from Paris64 using Lo-Tact-1 (rat IgG'b anti-p55) after 
kidney transplantation, CD25-positive (= IL-2R bearing) blood cells also remained 
undetectable during the 14-day treatment period. Rejection incidences in the Lo-
Tact-1 group and in the control group receiving ALG-induction treatment were 
similar, but infectious complications were less frequent in the anti IL-2R treated 
patients. On the basis of these results a large prospective randomized study 
using this monoclonal has been started in Paris. 
In liver transplantation a randomized trial using Lo-Tact-1 compared to an OKT3-
treated and to a control group receiving only triple drug therapy was done in 
Brussels, Belgium6'. Disappointingly, the overall rejection rates during the first 
3 months in the 3 groups were similar, although the percentages of steroid-
resistant rejection episodes proved to be lower in the 2 groups that were treated 
with monoclonals. Because of a higher CMV-incidence in the OKT3 treated 
group it was concluded that the combination of the triple drug treatment with 
Lo-Tact-1 had a better risk-benefit ratio in induction immunosuppression after 
liver transplantation. 
Another prophylactic study of the mAb YTH-906 in 100 liver transplant 
recipients in Cambridge and London, UK, did not result in differences in 
rejection, infection or survival either6'. The Heidelberg-group (Germany) 
presented data of a pilot study using BT563 (a murine IgG, anti IL-2R mAb) in 
liver transplantation, where a spectacular decrease in rejection incidence was 
found6'. Because of the small numbers and a historical control group their 
conclusion must however be regarded with caution. Nevertheless, using the 
same antibody, BT563, the liver transplant group in Berlin also achieved a lower 
incidence of early rejections compared to a historical control group treated with 
A TG6• 69 '0, a result that was confirmed in a randomized trial performed 
thereafter" . 
Limited experience was obtained in the use of anti IL-2R mAb for the treatment 
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of ongoing acute rejection. Cantarovich published results on 3383.1 treatment 
for acute rejection in renal allograft recipients". Only 2/10 patients responded 
immediately and unambiguously to 3383.1, and 4/10 of the cases responded 
with delay. Suggested explanations for this high failure-rate are the possibility 
that there was too much IL-2 or insufficient mAb at the rejection site. It could 
also be that the host immune response leading to graft destruction is no longer 
under IL-2 control at the time of treatment, but under the control of alternative 
activation pathways. In contrast, anti IL-2R mAb treatment was successful in 
the treatment of acute steroid-resistant graft-versus-host disease using 8-810 
(= 8T563)73 74 76 or humanized anti-Tac'·, although others using the 
antibody 2A3, had less positive results". Carl" published results on 
successful reversal of steroid-resistant acute interstitial renal rejection using 
8T563, but this study suffered from severe methodological errors and can not 
be regarded as support for efficacy of anti IL-2R monoclonals in the treatment of 
acute rejection. 
All of these murine or rat anti IL-2R monoclonals are immunogenic and elicit 
human anti-source antibodies in treated patients" 80. Some authors have 
reported reduced antibody formation against the mouse monoclonal 0 KT3 using 
concurrent administration of azathioprine" or cyclosporine82 during OKT3 
treatment. Another way to circumvent this problem is the use of chimeric and 
humanized antibodies, that are markedly less immunogenic and therefore have 
longer half lifes in vivo. A study with humanized anti-Tac in cynomolgus 
monkeys showed prolonged cardiac allograft survival in the animals treated with 
the humanized antibody compared to those treated with the murine 
monoclonal". The efficacy and safety of these anti IL-2R monoclonals in 
human organ transplantation remains to be proven, especially in view of the 
long half life of humanized monoclonals that may lead to prolonged 
lymphocytopenia and over-immunosuppression. 
The aim of this thesis is to investigate safety and efficacy of an anti IL-2R 
monoclonal (8T563) in the prevention of acute rejection after clinical heart and 
kidney transplantation. After having confirmed its potency in in vitro comparison 
with other anti IL-2R monoclonals, using inhibition of mixed lymphocyte 
reactions as a parameter, two large prospective clinical trials were started. In 
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kidney allograft recipients BT563 will be compared with placebo in a double-
blind randomized trial. In heart transplantation BT563 will be compared with our 
current policy of OKT3 as a rejection-prophylaxis in a randomized, non-blinded 
trial. 
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Chapter 2 
In vitro effects of BT563, an anti Interleukin-2Receptor monoclonal antibody. 
This chapter is based on an article published in Transplant International 
1994;7(Suppl1):S556-S558), entitled: In vitro and in vivo effects of BT563, an 
anti Interleukin-2Receptor monoclonal antibody, by Gelder van T. Daane CR, 
Vaessen LMB, Hesse CJ, Mochtar B, Balk AHMM, Weimar W. 
2.1 Abstract 
BT563, a murine anti IL-2R monoclonal antibody, was found to be more potent 
than anti-Tac in inhibiting proliferation in the mixed lymphocyte reaction. Results 
obtained with 33B3.1 in these experiments were similar to those with BT563. The 
anti IL-2R monoclonal antibodies 2A3, anti-Tac and 33B3.1 bind to an epitope of 
the same cluster on the IL-2R as BT563. 
2.2 Introduction 
Clinical organ transplantation has become a routine medical procedure. Although 
immunosuppressive therapy has improved considerably, graft rejection and 
complications of immunosuppression, such as the occurrence of infections and the 
induction of malignancies, still bother doctor and patient all too frequently. 
Monoclonal antibodies (MoAbs) directed against the Interleukin-2 receptor (IL-2R) 
are one of the results of the continuing search for better immunosuppressive 
agents '. The anti IL-2R MoAbs anti-Tac' and 33B3.1 3 are the two best 
documented examples of this new class of immunosuppressive agents. As a result 
of differences in the recognized binding site on the IL-2R the efficacy of these 
monoclonals may vary considerably'. Even within the p55 chain of the IL-2R 
several epitope clusters have been identified'. We describe in vitro results with the 
anti IL-2R MoAb BT563. 
2.3 Patients and methods 
BT563 (Biotest Laboratories, Dreieich - Germany) is a murine anti IL-2R MoAb of 
the IgG,-kappa isotype'. Anti-Tac is a murine anti IL-2R IgG" MoAb' and 2A3 is 
another murine anti IL-2R IgG, MoAb (Becton Dickinson). 33B3.1 is a rat IgG" 
MoAb3 (lmmunotech, France). All four monoclonal antibodies recognize epitopes 
on the p55 chain of the IL-2R. 
In vitro experiments. 
Peripheral blood lymphocytes (PBL) of healthy blood donors were cultured in a 
mixed lymphocyte reaction (MLR) for 7 days in RPMI-1640 (Dutch modification) 
supplemented with 10% human serum, 100 U/ml penicillin, 100 /lg/ml 
streptomycin and 2 mM glutamine at 37°C. Responder cells (5 x 10') were 
stimulated by 5 x 10' irradiated PBL (30 Gy) in triplicate in 96-well U-shaped 
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microtitre plates. MoAbs (BT563, 33B3.1 and anti-Tac) were added on day 0 to 6 
after the start of the MLR. Proliferation was measured after 8 hours of 'H-thymidine 
(1pCi/well) incubation. The effect of the MoAbs was determined as the percentage 
of inhibition of proliferation in the MLR. 
2.4 Results 
To monitor the effect of BT563 on peripheral blood we looked for an anti IL-2R 
MoAb that recognizes another epitope on the IL-2R. In the flow cytometric analyses 
we initially used unconjugated BT563 with fluorescein (FITC)-Iabelled goat anti-
mouse serum (GAM-FIlC) as a second step, and phycoerythrin (PE)-conjugated 
2A3. With this technique 2A3-PE appeared to be bound to free binding sites of the 
goat anti-mouse (GAM) antibodies in the BT563 GAM-FITC complex, making it 
unsuitable for monitoring the effect of BT563. By direct labelling of BT563 or 2A3 
with FITC this problem was solved. 
PE-conjugated 2A3 
FITC-Iabeled GoatAntiMouse 
BT563 
Interleukin-2Receptor 
Although initial experiments showed that after binding of FITC-conjugated BT563 
it was still possible for 2A3 to bind the IL-2R, we could not reproduce these results 
in later experiments. This was most likely caused by too low BT563 concentrations 
in the first experiments, leaving free binding sites for 2A3. Subsequential binding 
studies with combinations of the four monoclonal antibodies (BT563, 2A3, anti-
Tac, 33B3.1) showed that they all interfere with each others binding to the IL-2R, 
indicating that they recognize epitopes from the same cluster (Figure 2.1). 
Peripheral blood monitoring following BT563 treatment can therefore be performed 
using 2A3. Binding of 2A3 corresponds with free binding sites on the IL-2R. 
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Increasing concentrations of BT563 were first tested for their ability to inhibit 
proliferation in the MLR. As shown in Figure 2.2 lymphocyte proliferation was 
inhibited in a dose-dependent manner with maximal (86%) inhibition at 
concentrations above 500 ng/ml. The inhibition obtained with anti-Tac, also shown 
in Figure 2.2, was considerably less, with a maximal inhibition of 42.5%. Results 
with 33B3.1 were similar to those with BT563. 
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Figure 2.1 ABC Flow cytometry images of binding of the monoclonal antibody 2A3 
(y-axis) after BT563 administration (x-axis). using 20 ng/ml (A). 200 ng/ml (B) and 
2000 ng/ml (C) BT563. 
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Figure 2.2 Inhibition of lymphocyte proliferation in the MLR by increasing 
concentrations of 8T563 (B) and anti-Tac (+). 
If the monoclonal was added to the MLR on day 1, 2, 3 or even 4, 8T563 gave a 
maximal inhibition. Later addition no longer inhibited proliferation to this extent 
(Figure 3). Unlike 8T563, addition of anti-Tac on day 4 did not result in inhibition 
to the same extent as on day 0 (decrease from 42.5% to 20%). Again, with 
3383.1 we found an inhibitory effect similar to that of 8T563. 
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Figure 2.3 Inhibition of lymphocyte proliferation in the MLR by using three different 
monoclonal antibodies in a concentration of 2000 ng/ml (BT563 (.), 33B3.1 ( .. ). 
anti-Tac (+)). in relation to the day of addition after start of the MLR. 
2.5 Discussion 
BT563 is a murine IgG, anti IL-2R monoclonal antibody directed against the p55 
subunit of the IL-2R. This monoclonal is able to induce an 86% inhibition of MLR 
proliferation and was shown to be more potent than anti-Tac (42.5% inhibition). 
Even if administered after 4 days of culture, BT563 was able to give a similar 
degree of inhibition as on immediate addition to the culture medium. In contrast, 
the administration of anti-Tac after 4 days resulted in only 50% of the initial 
inhibitory effect. Both experiments using 33B3. 1 gave results similar to those with 
BT563. 
These results suggest BT563 to be an effective inhibitor of IL-2R mediated 
lymphocyte activation. The clinical value of this new immunosuppressive drug is 
currently under investigation. 
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Chapter 3 
In vivo effects and pharmacodynamics of prophylactic antirejection therapy with 
an anti Interleukin-2Receptor monoclonal antibody (8T563) after heart and 
kidney transplantation. 
This chapter is based on the following articles: 
Peripheral blood monitoring during and after rejection-prophylaxis with a 
monoclonal anti Interleukin-2Receptor antibody in kidney and heart transplant 
recipients, by Gelder van T, Knoop CJ, Hesse CJ, Vaessen LMB, Balk AHMM, 
Yzermans JNM, Weimar W, in Transplantation Proceedings 1995;27:B56-868. 
and 
Pharmacodynamics of prophylactic antirejection therapy with an anti-Interleukin-
2Receptor monoclonal antibody (BT563) after heart and kidney transplantation, 
by Hesse CJ, Gelder van T, Vaessen LMB, Knoop CJ, Balk AHMM, Yzermans 
JNM, Jutte NHPM, Weimar IN, in Immunopharmacology 1995;30:237-246. 
3.1 Summary 
A mouse monoclonal antibody (BT563) directed against the a-chain of the IL-2 
receptor was administrated immediately after transplantation in a dose of 10 
mg/day prophylactically to 30 heart transplant recipients and 42 renal transplant 
recipients to induce immunosuppression. Plasma levels increased to a plateau 
level of 5300 ng/ml in the heart and 5900 ng/ml in kidney recipients. BT563 
plasma disappearance curves give a mean T y, of 39 hour (range 14 - 112) and 
42 hour (range 8 -122) for heart and kidney respectively. The CD25 marker (IL-
2R) on peripheral blood lymphocytes was coated with BT563 within hours after 
the first gift and returned to normal within 0 - 20 days after the last gift. In 
heart transplant recipients more often CD25 + cells were found in the presence 
of BT563 and more rejections occurred shortly after discontinuation of BT563 
compared to the kidney recipients. Rejectors and nonrejectors within the heart 
transplant group did not differ with respect to the period that CD25 positive 
cells in peripheral blood were BT563 coated. In 56% of the patients a substan-
tial IgM antibody response was detected. This response was similar for heart 
and kidney and not related to rejection. The frequency of IgG responses was 
low in both heart (13%) and kidney (21%) patients and the IgG response was 
not related with graft rejection or with antirejection treatment. Peripheral 
monitoring showed that monoclonal antibody plasma levels, antimurine antibody 
responses and coating of CD25 positive cells were not related with the clinical 
results. BT563 proved to be safe with respect to the generation of antimurine 
antibodies and, when given in combination with cyclosporin, is a therapy with a 
potential for high efficacy. 
3.2 Introduction 
The use of murine monoclonal antibodies (mAbs) in rejection prophylaxis or 
therapy is helpful in suppressing the recipient immune response during the first 
weeks after clinical transplantation as has been described extensively' 2 3 '. 
The most frequently used mAb is OKT3 (anti-CD3), a pan-T cell mAb with 
proven efficacy'. One of the drawbacks of the use of this mAb is the so-called 
cytokine release syndrome, associated with the first gift(s). resulting in fever, 
chills and hypotension in most patients. For that reason and the fact that all T-
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cells irrespective of their involvement in rejection are affected, there is an 
ongoing search for more specific therapeutic strategies with less side-effects. 
A more selective approach toward immunosuppression would be to target only 
activated T-cell clones via the interleukin-2 receptor. Interleukin-2 and the 
interleukin-2 receptor complex (IL-2R, CD25) play an important role in the 
activation and proliferation pathway of T-Iymphocytes. The IL-2R complex 
consists of at least three distinct membrane components: the 55-kDa a-chain 
(IL-2Ra) or Tac antigen, the 70175 kDa B-chain (IL-2RB) and a 64 kDa v-chain 
(lL-2Ry). Activated T-cells express the inducible IL-2Ra chain whereas resting 
cells and their precursors do not. The interaction of alloantigens with the T-cell 
antigen receptor complex (TCR) induces the expression of interleukin-2 and its 
homologous receptor on the T-cell surface resulting in proliferation of these 
cells. Disturbing the latter process by blocking the receptor with a monoclonal 
antibody should prevent the onset of the rejection process. Soulillou et ai' and 
Kirkman et ai' reported positive effects of prophylactic use of anti-IL-2Ra 
monoclonal antibodies on graft survival in renal transplantation. In the present 
study we report the in vivo consequences of prophylactic use of the mAb 
BT563 such as effectiveness of CD25 coating, mAb levels and half-life in 
plasma and human antimouse antibody (HAMA) responses. Blood samples were 
obtained from kidney transplant recipients in a BT563 versus placebo double-
blind controlled study and from heart transplant recipients in a BT563 versus 
OKT3 study. Clinical results of both studies were reported in detail elsewhere" 
9 
3.3 Materials and methods. 
Monoclonal antibodies. BT563 (Biotest Pharma, Dreieich, Germany), previously 
known as B-B10, is a murine mAb of the IgG1-kappa isotype and directed 
against the p55 or a-chain of the IL-2R complex'o (Wijdenes et al. 1989). 
Orthoclone OKT3 (Cilag, Schaffhausen, Switzerland) is a murine IgG2a mAb 
directed against the T-cell receptor associated CD3-complex. 
Patients. BT563 was given as rejection prophylaxis to 72 allograft recipients (30 
heart and 42 kidney) in a daily dose of 10 mg in a sequential treatment scheme 
including cyclosporin A (CsA) and prednisone. Kidney transplant recipients 
received 10 daily doses of BT563 (days 0-9) and simultaneously CsA was 
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started at day O. Initially, twelve patients participated in a pilot study with 
BT563. The other 30 kidney allograft recipients were treated with BT563 during 
a double-blind, placebo-controlled trial, of which the results are shown in 
chapter 6. In the kidney transplant recipients, cyclosporin was started on day 0 
at a dose of 2 mg/kg per day i.v. until day 3, and at 8 mg/kg per day orally 
thereafter, aiming at whole blood levels of 300 to 350 ng/ml 
(radioimmunoassay). The diagnosis of acute rejection was made on clinical 
grounds by the responsible nephrologist, and was confirmed by core needle 
biopsy. Clinical indicators of acute rejection included rising creatinine, oliguria, 
fever and graft tenderness. 
BT563 (10 mg/day) or OKT3 (5 mg/day) was given for 7 days (days 0-6) to the 
heart transplant recipients and CsA was given from the third postoperative day, 
in a dosage of 8 to 10 mg/kg per day, aiming at whole blood levels of 400 
ng/ml. In addition heart transplant recipients received 50 mg azathioprine daily 
during the first week. Endomyocardial biopsies were performed weekly during 
the first 6 weeks after transplantation. These biopsy specimens were graded 
histologically according to the criteria of the International Society for Heart and 
Lung Transplantation ". Specimens graded as 3A, 3B or 4 were regarded to 
represent rejection episodes necessitating antirejection therapy. Acute rejections 
were initially treated with gram methylprednisolone (Solu-Medroll 
intravenously on three consecutive days. Steroid-resistant rejections were 
treated with a fourteen days course of rabbit anti-thymocyte globulin. 
Flowcytometric analysis. Peripheral blood of the patients receiving BT563 or 
OKT3 was monitored daily for lymphocyte subsets during the first ten 
postoperative days and twice weekly thereafter until the uncoated IL-2R (CD25) 
or the TCRaB-chains (WT31) respectively returned on the surface of the T-cells. 
T-cells Were monitored with mAb against CD3, CD4, CD5, CD8 and HLA-DR 
(lmmunotech, Marseille, France), TCR-aB (WT31) and CD25 (2A3) (Becton-
Dickinson, Mountain View, Ca, USA) conjugated to fluorescein isothiocyanate 
(FITC) or phycoerythrin (PE). The mAb 2A3 recognizes an epitope on the IL-2Ra 
chain of the same cluster as BT563 and will only bind if BT563 coating has 
disappeared". T-cell subsets were quantified by two colour analysis in a 
combination with anti-CD3 PE conjugated mAb (clone UCHT1) after BT563 or 
with an anti-CD5 PE conjugated mAb (lOT1 a) after OKT3. Analyses were 
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performed on a FACScan flow cytometer (Becton-Dickinson) using Simulset 
software (Becton-Dickinson) with CD45 and CD14 as lymphocyte gate and as 
isotype controls murine IgG 1 and IgG2a. In case of nonspecific binding of the 
mAbs, plasma was removed before staining by washing the blood cells with 
RPMI1640 + 1 % bovine serum albumin (BSA). Persistent nonspecific staining 
was reduced by washing with the RPMI1640 solution containing an irrelevant 
mouse mAb. 
Plasma BT563 and OKT3 levels were determined with an ELISA sandwich 
method. 96-wells enzyme immunoassay microtiterplates (Maxisorb, Nunc, 
Roskilde, Denmark) were coated overnight with 100 III goat antimouse-lgG 
(Southern Biotechnology Associates, Birmingham, AL, USA) as capture antibody 
in phosphate buffered saline (5Ilg/ml). After washing with Tris buffered saline 
containing 0.05% Tween 20 (TBS/Tw), free binding sites on the plates were 
blocked with TBS/Tw containing 1 % bovine serum albumin. A standard curve 
was constructed with parental grade BT563 and OKT3 in TBS/Tw/ containing 
0.2 % BSA and ranged from 0.05 to 75 ng/ml. Appropriate plasma dilutions 
were selected to measure BT563 and OKT3 in the range of 20 - 10.000 ng/ml 
and 4 - 2.000 ng/ml respectively. Alkaline-phosphatase-conjugated goat 
antimouse-lgG antibodies (Southern Biotechnology Associates) were used as a 
detector antibody and p-nitrophenyl phosphate as substrate. 
Human antimouse antibodies (HAMA's) were determined with an ELISA method 
using BT563 and OKT3 coated microtiterplates. The microtiterplates were 
coated overnight with 100 III BT563 or OKT3 (5 Ilg/ml) in phosphate buffered 
saline. After washing and blocking with TBS/Tw, plates were filled with serial 
dilutions of plasma samples in TBS/Tw/0.2% BSA (dilutions 1 :50 - 1 :6400). The 
IgG and IgM HAMA's were quantified with Alkaline-phosphatase-conjugated 
goat antihuman IgG (Fc specific) or Alkaline-phosphatase-conjugated goat 
antihuman IgM (Fc51l specific) (Jackson Immuno Research Laboratories, West 
Grove, PA, USA) and compared with a standardized plasma sample obtained 
from a patient with a clear IgG and IgM antibody response after BT563 
treatment. IgM titre for this standard sample was set on 1000 arbitrary units 
(AU). The reference IgG anti-BT563 antibody concentration was measured as 
previously done for anti-OKT3 antibodies 13 and was assessed to be 154 mg/L . 
All samples were tested on BT563 (lgG1-isotype) and OKT3 (lgG2a-isotype) 
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coated microtiterplates to discriminate for isotype specificity. 
Soluble IL2 receptor. Soluble IL2 receptor concentration in plasma was 
measured with an enzyme immunoassay (sIL-2r, Immunotech) according to the 
manufacturers instructions. The assay is a sandwich ELISA test using murine 
mAbs as coating and detecting antibodies. 
Statistical methods. The significance of the differences between sample means 
was assessed by the Mann-Whitney U-test. Fisher's exact test was used to test 
associations between categorical variables. 
3.4 Results. 
Clinical results. 
None of the 12 renal transplant patients who received BT563 in the pilot study 
did have an acute rejection. Of the 30 renal transplant recipients who received 
BT563 in the placebo-controlled trial only 3 patients experienced an acute 
rejection episode within the first three months. In all three CD25 + cells had 
reappeared in the peripheral blood. At the end of the BT563 administration 
period in the heart transplant recipients 14/30 patients had an acute rejection 
(first week endomyocardial biopsy graded as 3A or 3B). This group of fourteen 
patients is further named rejectors and the other sixteen patients are further 
named non-rejectors. Rejections were treated with 1 gram methylprednisolone 
(Solu-Medrol) intravenously on three consecutive days. Steroid-resistant 
rejections were treated with rabbit anti-thymocyte globulin (RIVM, Bilthoven, 
The Netherlands). 
BT563 plasma levels. 
Comparable pharmacokinetics of BT563 were found in heart and kidney 
transplant recipients. The maximal plasma levels (5900 ± 200 ng/ml, mean of 
day 6 - 10, ± SEM) observed in the kidney transplant recipients were slightly 
higher than the mean peak levels (day 6 - 8) of the heart transplant patients 
(5300 ± 200 ng/mi) (Fig 1). The half-life values (T y,) of BT563 in blood 
calculated from the descending part of the disappearance curves of both groups 
of patients using a one-compartment model, were almost similar for kidney (T y, 
= 42 ± 5 hr) and heart transplant patients (T y, = 39 ± 3 hr). The half-life 
values of the individual patients were highly variable and ranged from 14 to 112 
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hours (median = 40 hr) in heart transplant recipients and from 8 to 122 hours 
(median = 48 hr) in kidney recipients and were not significantly different 
between both groups of patients (p = 0.1406). The differences in the plasma 
T" between the fourteen heart transplant rejectors (median 38.2 hr) and the 
sixteen non·rejectors (median 44.2 hr) were not quite significant (p=0.0559). 
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Figure 3.1 Pharmacokinetics of BT563 and OKT3 in heart transplant recipients 
(HTX) receiving BT563 (7 daily doses of 10 mg, n = 30) or OKT3 (7 daily doses 
of 5 mg, n = 20) and renal transplant recipients (RTX) receiving BT563 (10 daily 
doses of 10 mg, n = 40). Mean trough levels ± SEM. 
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The effect of BT563 on peripheral blood cells. 
The selective disappearance of free IL-2 binding sites by BT563 administration in 
heart transplant recipients is demonstrated in figure 3.2. The initial decrease of 
the total number of lymphocytes is an effect of steroid administration 
immediately after transplantation. The CD25 + cells are coated with the antibody 
within hours after the first gift of BT563 and coating persisted (last negative 
count for 2A3 binding) for a period of 13 days (median, range 8 - 19 days) in 
heart transplant recipients (N = 30). Blood samples were scored as positive if 
10% or more of all T-cells had a positive staining for the CD25 marker. The 
median period of coating of CD25-positive cells in the group of rejectors was 
not significantly different from the group of non-rejectors (median 13.0 vs 13.5 
days, p=0.4410). 
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Figure 3.2 Monitoring the effect of BT563 on CD25 positive cells after heart 
transplantation. Mean concentrations and SEM of T-cells and T-cell subsets in 
the peripheral blood (n = 25). 
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In the kidney transplant recipients (N = 37) the median period of coating of 
CD25 + cells in peripheral blood was 16 days (range 10 - 30 days). 
After BT563 treatment in all patients CD25 + cells returned to normal numbers 
(10% to 25% of the lymphocytes) without a significant increase in the number 
of T-cells (CD3+ and WT31 +) indicating that the IL-2R indeed had been coated 
by the antibody. 
Figure 3.3 shows the percentage of patients without free CD25 +binding sites at 
different days post transplantation. 
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Figure 3.3 Plot of the percentage of heart transplant recipients (HTX, n = 30) 
and renal transplant recipients (RTX, n = 38) without free IL-2 binding sites 
(CD25) in peripheral blood cells in relation to the time after transplantation. 
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In most patients BT563 plasma levels returned to below the detection limit 
before free CD25 binding sites were detected in peripheral blood. However, in 8 
of 55 patients the a-chain of the IL2-receptor on T-cells reappeared in the 
presence of a substantial level of circulating BT563 (arbitrarily chosen as > 100 
ng/ml). With this arbitrary value, in heart transplant recipients significantly more 
often positive CD25 + cell counts coincided with positive BT563 plasma levels (7 
out of 25 patients) compared with renal transplant recipients (1 out of 30 
patients), p = 0.0175, Table I. The distribution of these heart transplant 
patients over the group of rejectors (2114) and non-rejectors (5/16) proved to be 
not significantly different (p = 0.3992). 
Tabla I. Recurrence of uncoated CD25' T-cells In the presence of detectable 
BT563 plasma levels (> 100 pg/L) 
number of patients 
kidney transplants 1/30 
heart transplants' 7/25 
days posltransplantation 
23 
12,13,13,13,17,19, 
19 
• 5 patients were not included because incompleteness of data. 
Generation of anti-mouse antibodies. 
A wide range of pre-existing HAMA levels (1-42 mg/L IgG antibodies, 10-600 
AU IgM antibodies) was found in these patients. Therefore, to express the 
induction of human anti mouse antibodies after BT563 and OKT3 therapy, the 
relative increases of the antibody concentration and not the absolute antibody 
levels were used (Table II). Values over four times the pretransplant or day zero 
value were sufficient dissimilar to consider as a positive HAMA reaction. No 
difference in the number of patients with a positive HAMA response of IgM or 
IgG antibodies was found between the heart and kidney transplant recipients in 
spite of the longer administration period in the kidney recipients and the higher 
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level of immunosuppression in the heart transplant patients. The IgM response 
became positive between day 9 and day 18 (median at day 13) in the BT563 
treated heart transplant recipients and between day 6 and 59 (median 18 days) 
for the kidney transplant group. 
In almost all BT563 treated patients the HAMA binding to BT563 (lgG,) and 
OKT3 (lgG,,) coated microtiterplates demonstrated an identical ratio in time after 
transplantation (results not shown). In only 4 patients a clear variation of this 
ratio in time after administration of BT563 was found which suggests an extra 
contribution of isotype and/or idiotype specific antibodies. 
An increase of IgM HAMA could result in increased removal of circulating 
BT563 and in occurrence of acute rejection in heart or kidney transplant 
recipients. For heart recipients however the opposite relation was found after 10 
days and less after 17 days, probably because of extra immunosuppression (fig 
4). Considering in the first 2 months an increase of IgM HAMA concentration 
with a factor 4 as positive, we found a positive score in 7 out of 14 heart 
transplant patients with a rejection within one week after transplantation, in 5 
out of 11 patients with a rejection more than one week after transplantation and 
in 4 out of 5 patients without any rejection during the period studied. 
In 17% of the heart and kidney transplant recipients positive IgG antimurine 
responses were found after 15 to 47 days. All these patients also showed a 
positive IgM HAMA response but the clinical picture of these patients was not 
different from the patients without IgG response. Two patients with positive IgM 
and IgG responses were found within the group of fourteen heart transplant 
rejectors and the other two were found within the sixteen nonrejectors. 
BT563 versus OKT3. 
In the heart transplant patients receiving 5 mgfday OKT3 the maximal mAb 
plasma levels achieved (950 ± 80 ng/ml at day 6) and the mAb half·life (T" = 
21 ± 2 hr) were substantially lower compared with the group of patients 
receiving 10 mg/day BT563 (previous section, fig 3.1). In 2 out of 20 patients 
OKT3 levels decreased already before the end of the administration period 
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Figure 3.4 Relative increase of IgM HAMA at 10 and 17 days after heart 
transplantation in rejectors (n = 14) and non-rejectors (n = 16). Comparison of 
rejectors and non-rejectors at day 10 (p = 0.0340) and at day 17 (p = 0.0674). 
coincident with increased IgM and IgG HAMA levels. 
The effect of OKT3 administration is a strong reduction of all subsets of T-
lymphocytes in the peripheral blood in contrast to the effect of 8T563 (fig 5). 
TCRai?> + (WT31 +) cells already reappeared at 5 days (mean, range 3-9 days) 
after finishing OKT3 administration. In 8T563 treated patients the CD25+ cells 
reappeared on a mean of 10 days (range 5-22 days) after the end of treatment. 
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Figure 3.5 Effect of OKT3 on the number of T-cells and T-cell subsets in heart 
transplant recipients (n = 20, mean ± SEM). After initial depletion T-cells 
returned modulated for the T·cell receptor (CD3 positive and WT31 negative 
lymphocytes). 
No difference was found between the BT563 and OKT3 treated heart transplant 
patients with respect to the number of patients with a positive HAMA response 
of IgM antibodies (Table II). However, the IgM response was detected earlier 
after OKT3 than after BT563 treatment. In 55% of the patients treated with 
OKT3 an IgM response was found in the first sample tested (day 5-7 post 
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transplantation). Also the IgG response was earlier in the OKT3 treated group 
and became positive between day 7 to 21 (median day 14). For IgG antibodies, 
in contrast to IgM antibodies, the number of responders was higher in the OKT3 
group (55%) compared with the 8T563 heart transplant (13%, p = 0.0036) 
and kidney transplant recipients (21 %, p = 0.0174). Nine OKT3 treated 
patients showed an relatively increased IgG HAMA response measured on OKT3 
coated microtiterplates compared to 8T563 coated plates which indicates an 
idiotype and/or murine IgG2a isotype specific reaction. 
A high disappearance rate of the mAbs (OKT3 as well as 8T563) in the plasma 
of the individual patient (a low T y, ) was not related with the IgM or IgG 
response. (results not shown). 
Table II. HAMA response after monoclonal antibody (9T563 or OKT3) treatment. 
IgM antibody IgG antibody response 
response 
organ and negative positive.!! negative positive! 
treatment 
RTX 9T563 12 17 23 6 
HTX 9T563 14 16 26 4 
HTX OKT3 8 12 9 11 
a positive is an increase over 4 times the pretransplant value. 
Soluble IL-2 receptor. 
In one patient treated with 8T563 the s1L-2 receptor concentrations in plasma 
were measured at regular intervals up to 60 days after transplantation (fig 6). 
During 8T563 treatment there was a reduction of sIL-2R followed by a clear 
increase in the period thereafter. This patient generated also a HAMA IgM 
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response which was maximal around day 20 (8 times pretransplant levell and a 
HAMA IgG response between 35 and 60 days. The HAMA IgG concentration 
increased from 11 mg/L to 63 mg/L at day 41. Addition of BT563 to a sIL-2R 
standard sample reduced the measured value illustrating that circulating BT563 
can influence the measured sIL-2R plasma levels. 
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Figure 3.6 Soluble IL-2 receptor in plasma in a single patient after heart 
transplantation. The patient received 7 doses of 10 mg BT563 (days 0-6). 
Biopsy proven rejection was treated with rabbit anti-thymocyte globulin (rATG). 
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3.5 DISCUSSION. 
The BT563 doses given proved to be very effective in coating the IL-2R a-chain 
on T-cells during the administration interval and a period thereafter. The free IL-
2R a-chain on T-cells was reduced below the detection level". Cell bound BT563 
could be demonstrated with a PE-Iabeled rat anti-mouse antibody. In 8 patients 
(7 heart transplant recipients and only 1 renal transplant recipient) the IL-2a 
chain became detectable on T-cells concurrent with a substantial level of BT563 
in the circulation, however. This means that in the heart transplant group, in 
spite of a shorter course of BT563 but with plasma levels during the 
adminstration period comparable with the kidney transplant group, the 
monoclonal antibody levels are not sufficient to suppress the reappearance of 
free a-chains of the IL2-receptor on the circulating blood cells in the presence of 
the mAb in a number of cases. The plasma levels obtained are far above the 
levels needed for inhibition of T-cell proliferation in vitro. We have demonstrated 
a maximal inhibition of lymphocyte proliferation in the mixed lymphocyte 
reaction already at BT563 levels of 500 ng/ml". This inability to prevent the 
reappearance of CD25 was not directly related to the generation of antimurine 
antibodies as only 2 of these 7 heart transplant patients had an increased IgM 
response over 4 times the pretransplant level. Immune complex formation can 
explain this phenomenon in the renal transplant recipient. In this patient an 
abrupt increase of IgG HAMA was found at day 14, while the highest IgM 
HAMA titre were found between day 23 and day 28. BT563 was still detectable 
in the plasma (600 ng/ml) at day 23 together with 36% CD25+ T-cells. 
A mean distribution volume of 3.0 litre in kidney recipients and 2.6 litre in heart 
recipients was calculated based on the daily gift of 10 mg BT563 and the 
resulting mean plasma levels measured 24 hours thereafter. With a daily dose of 
5 mg OKT3 a distribution volume of 4.1 litre was calculated. This indicates that 
most of the antibodies stay in the circulation and that the tissue concentration 
may be low. Because BT563 is a coating and not a modulating or a depleting 
mAb, cells infiltrating the graft may generate the free IL-2 receptor quickly on 
the cell membrane, resulting in intragraft lymphocyte proliferation. Indeed, in 
endomyocardial biopsies protocollary taken within the BT563 treatment period 
(at day 7) we found uncoated CD25 + T-cells after immunohistological 
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staining 14. 
After the last gift the plasma levels dropped in a few days below the detection 
level as a result of the high disappearance rate of both mAbs BT563 and OKT3. 
Short half-lives of mAbs in the circulation, (21-42 hrs) compared to 21 days for 
human IgGs, were also mentioned by others'5 " ". The plasma half-life of 
the mAbs will be influenced by the epitope density on the target cells, the 
number of cells carrying that epitope, and the regeneration of the epitope on 
these cells. The higher density per cell and the presence of the CD3 determinant 
on more cells compared to the p55 chain of the IL2-receptor may explain the 
difference in half-life observed between OKT3 and BT563. A reasonable 
explanation for the short half-life compared with human IgG is the existence of 
natural antimouse antibodies. Galili has described the expression of an a-
galactosyl carbohydrate epitope on cells of nonprimate mammals and the 
presence of naturally occurring anti-Gala1-3Gal antibodies in the human 
population '8 '9. Borrebaeck and co-workers proved the existence of this 
glycosylation of mouse monoclonal antibodies to a degree which is mAb 
dependent'o. The presence of these natural antibodies in human serum results 
in a quick removal of the mouse mAbs. Indeed mouse/human chimeric 
antibodies and humanized monoclonals have a longer in vivo survival, are 
substantially less immunogenic than their murine counterpart, and have a better 
efficacy as shown in primate cardiac allograft survival" and treatment of colon 
cancer in humans21 . 
The reason why a high number of rejections in the first period of treatment with 
BT563 in the heart transplant group was found compared to the kidney 
transplant group, in spite of similar BT563 levels and similar HAMA generation, 
can possibly be the difference in the immunosuppressive protocols for both 
groups of patients. The additional gift of CsA immediately after transplantation, 
as done in kidney transplantation, is perhaps required for an effective block of 
the activation of the T-cells. 
The BT563 treated patients have a low incidence of IgG antibody induction 
compared with the patients treated with OKT3 for the same period. This could 
be caused by a functional effect of BT563 on T- and B-cells and the signal 
needed by B-cells to switch from IgM to IgG antibody production. The fact that 
treatment with other a-IL-2R mAbs (33B3.1 and anti-Tac, both IgG,,) results in a 
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strong response of neutralizing IgM and IgG antibodies favours another 
explanation, however. Soulillou' reported the generation of IgM and IgM 
antibodies in 80% of the patients one month after treatment with mAb 33B3.1 . 
Similarly treatment with anti-Tac resulted in anti-murine antibodies in more than 
60% of the patients'. Maybe differences in the subclasses of the mAbs (lgG, 
versus IgG,,) can account for the different immune response. Three major 
classes of receptors for IgG on human leucocytes, hFcyRI, hFcyRIl and hFcyRlI1, 
are currently recognized which possess different affinities to the separate human 
and mouse IgG isotypes". For the hFcyRIl expressed on B-cells the affinities 
for murine IgG isotypes were found as 1 > 2 > > > 2a,3. This hFcyRIl has an 
important function in regulating B-cell activation through membrane 
immunoglobulin. Crosslinking of this hFcyRIl with membrane immunoglobulin by 
murine IgG would deliver a dominant negative signal to B-cells leading to 
inhibition of both proliferation and production". Maybe this inhibition is 
responsible for the low induction of IgG HAMA titre with BT563 (lgG,). 
In a pilot experiment in a single patient the sIL-2R concentrations in plasma 
during and after BT563 therapy were followed. Unfortunately the measurement 
of sIL-2R plasma levels are negatively biased by circulating BT563. The 
formation of HAMA can also influence the test results resulting in apparent high 
values as found between day 15 and 30. To avoid these influences the test has 
to be modified by using antibodies of a different species or adding irrelevant 
murine immunoglobulin and changing the incubation protocol. 
In conclusion, BT563 therapy results in coating of CD25 + T cells, while inducing 
low levels of IgG antibodies in only 17% of the patients. It is therefore useful in 
induction of immunosuppression if given together with cyclosporin. Results of 
peripheral monitoring of mAb plasma levels, HAMA responses and number of 
CD25 positive cells were not related with the clinical results. The low levels of 
induction of IgG HAMA's allows future reuse of the mAb BT563. 
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Chapter 4 
A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti 
Interleukln-2Receptor antibody (BT563) in the prevention of acute rejection after 
heart transplantation. 
This chapter is based on an article with the same title, accepted for publication in 
Transplantation, by Gelder van T, Balk AHMM, Jonkman F, Zietse R, Zondervan P, 
Hesse CJ, Vaessen LMB, Mochtar LMB, Weimar W. 
4.1 Abstract 
In a prospective randomized trial 8T563, a murine IgG, anti Interleukin-2Receptor 
antibody, was compared with OKT3 as early rejection prophylaxis after heart 
transplantation. Patients received either 8T563 (n = 31) or OKT3 (n = 29) during the 
first 7 days after transplantation; cyclosporin was started on day 3. Median follow-
up is 34 months. 
A cytokine release syndrome occurred in the majority of patients of the OKT3 
treated group but in none of the 8T563 recipients. The mean duration of electrical 
stimulation of the heart in the 8T563 group was longer than in the OKT3 group 
(5.1 vs 2.1 days). In both groups insertion of a permanent pacemaker was 
neccessary in one patient. 
Freedom from acute rejection at 3 months Was not significantly different between 
the 2 groups (8T563: 5/29 = 17% ; OKT3: 6/29 = 21 %). In the 8T563 group 
however, rejection tended to occur earlier after transplantation. There was no 
difference in the overall incidence of rejection. Infectious complications were evenly 
distributed in both groups. Malignancies occurred in two patients, both in the OKT3 
group. 
In conclusion, the use of this anti IL-2R MoAb in heart transplant recipients is safe 
and devoid of the side effects that accompany the use of OKT3. OKT3 and 8T563 
result in a similar freedom from rejection at three and twelve months after heart 
transplantation. 
4.2 Introduction 
The murine monoclonal anti-CD3 antibody OKT3 exerts its in vivo 
immunosuppressive effects by inducing major peripheral T cell depletion as well as 
antigenic modulation of the T-cell receptor complex'. Although effective as anti-
rejection therapy and possibly as rejection prophylaxis in heart and kidney 
transplantation' " the administration of OKT3 is accompanied by a cytokine 
release syndrome4 and by procoagulant effects' that may result in intragraft 
thrombosis and graft loss. The OKT3-induced profound and aspecific 
immunosuppression can be accompanied by an increased incidence of infectious 
complications' and by the development of malignancies'. Monoclonal antibodies 
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directed at activated lymphocytes only, lead to a more specific immunosuppression 
and might therefore circumvent these problems. 
In contrast to resting T-cells activated T-cells, involved in allograft-rejection, 
express high-affinity Interleukin-2Receptors (IL-2R)·. The use of monoclonal 
antibodies directed against the IL-2R (IL-2R MoAbs) proved to result in prolonged 
graft survival in animal models' '0. Thereafter clinical trials with several different 
IL-2R MoAbs were performed in the prevention of acute rejection after kidney 11 12 
", combined kidney and pancreas" and liver" ,. transplantation. Here we 
present the results of a controlled trial with BT563, a murine IgG,-antiIL-2R MoAb, 
compared with OKT3 as early prophylaxis against rejection after heart 
transplantation. 
4.3 Patients and Methods 
Between November 1991 and February 1994 sixty consecutive recipients of a 
cardiac allograft were randomized for prophylactic anti-rejection treatment with 
BT563 or OKT3 after returning from the operation theatre. BT563 (Biotest Lab.-
Dreieich Germany) was given in a dosage of 10 mg i.v. from day 0 to day 6 after 
transplantation. OKT3, 5 mg iv daily, was given following the same protocol. In 
addition to BT563 or OKT3 patients were treated with prednisone 50 mg daily from 
day 0, gradually decreasing to 15 mg at 4 weeks after transplantation. Cyclosporin 
was started at day 3 in a dosage of 8 mg/kg/day, aiming at whole blood trough 
levels of 400 - 500 ng/ml (radioimmunoassay). When the thrombocyte-count was 
above 100. 10'/ml, 50 mg azathioprine was given for the first 6 postoperative 
days in an attempt to prevent the formation of anti-murine antibodies". 
Endomyocardial biopsies were performed weekly during the first 6 weeks, biweekly 
during the next month and monthly for the next four months after transplantation. 
Biopsies were repeated more frequently after a rejection episode. 
Peripheral blood monitoring. 
Before, during and after BT563 treatment peripheral blood samples were collected 
daily in EDTA containing tubes and monitored for the presence of T cell subsets by 
two color flowcytometry using MoAb directly conjugated to fluorescein (FITC) or 
phycoerythrin (PE). Prior to incubation with MoAb, 100/11 whole blood was washed 
twice with 2 ml phosphate buffered saline to remove BT563 and human-anti-mouse 
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antibodies that might interfere with the staining procedures. Subsequently 20 pi of 
the following dual MoAb combinations were added to 100 pi cell suspensions: 
CD45-FITC/CD14-PE; IgG,-FITC/lgG,.-PE as isotype controle; CD3-FITC/CD19-PE; 
CD3-FITC/CD8-PE; CD3-FITC/CD4-PE; CD4-FITC/HLA-DR-PE, all obtained from 
Immunotech (Marseille, France); and the combination WT31-FITC (anti-TCRa/B) 
/CD25-PE (MoAb 2A3) both obtained from Becton & Dickinson (San Jose, 
California). After 30 minutes incubation at room temperature, red blood cells were 
lysed with FACS lysing solution (Becton & Dickinson) during 10 minutes. After 
washing, cells were analysed on a FACScan (B&D) flow-cytometer using SimulSet 
software (B&D) for data analysis. To establish an analysis gate that included at 
least 90% of the lymphocytes the CD45/CD14 reagent was used. 1000 to 2000 
lymphocyte events were acquired from each tube. 
The CD25 MoAb 2A3 is also directed against the IL-2R a-chain, and is competitive 
with BT563'8. In a number of patients we also analysed the presence of the 
CD122 (lL-2R B-chain (p75)) on the T-Iymphocytes by the MoAb combination TIC-
1-FITC (Endogen, Boston, MA) / CD3-PE (Immunotech). APE-conjugated polyclonal 
rat-anti-mouse antibody (RAM) (B&D) was used to determine whether CD25-
positive cells in PBL were coated with BT563 during treatment. 
Plasma BT563 levels. 
BT563 trough levels were measured daily during treatment. Plasma levels were 
determined with an ELISA sandwich method using goat antimouse-lgG (Southern 
Biological Associates, Birmingham, AL, USA) and alkaline-phosphatase-(AP)-
conjugated goatantimouse-lgG (H + L) antibodies (Jackson Immuno Research, West 
Grove, PA, USA). Samples were diluted 1 :450 and 1 :2000 with Tris buffered 
saline/Tween 20/Bovine Serum Albumine (TBS/Tw/BSA). The concentration of 
BT563 was estimated by interpolation of obtained values on a standard curve of 
parental grade BT563 diluted in TBS/Tw/BSA. 
Anti BT563-antibodies. 
Anti BT563-antibodies were measured in an ELISA system using microtiterplates 
pre coated with 0.1 ml BT563 solution (3 pg/ml Phosphate Buffered Saline (PBS), 
pH 7.4). Plasma samples were initially 1 :50 diluted and fUrther in double dilution 
steps of 0.1 ml PBS. Human antibodies were detected with an AP-conjugated goat 
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antihuman-lgG antibody (Jackson Immuno Research) and quantified by comparison 
with two different reference plasma samples. The concentration of antimouse-lgG 
antibodies in these reference plasma's was 54 and 154 pg/ml respectively. 
Rejection: monitoring and treatment. 
A pathologist, unaware of the immunosuppressive protocol, examined EMB-
specimens stained with hematoxylin-eosin using light microscopy. Biopsies were 
graded according to the guidelines of the International Society for Heart and Lung 
Transplantation!· (Table 4.1). Biopsies graded 3A or higher were regarded to 
represent rejection episodes neccessitating anti·rejection treatment. In the majority 
of cases rejection was treated with 1 gram methylprednisolone (Solu-Medrol) Lv. 
on three consequetive days. Frequently recurring or refractory rejection episodes 
were treated with rabbit-ATG (RIVM, Bilthoven, The Netherlands). Recurrent 
episodes of steroid-unresponsive rejection after treatment with r-A TG were treated 
with a course of OKT3. 
Table 4.1 Criteria for standardized cardiac biopsy grading. 
(J Heart Transpl 1990;9:587-593) 
Grade Histology 
o no rejection 
1 A focal infiltrate without necrosis 
1 B diffuse but sparse infiltrate without necrosis 
2 one focus only with aggressive infiltration and/or focal myocyte 
damage 
3A multifocal aggressive infiltrates and/or myocyte damage 
3B diffuse inflammatory process with necrosis 
4 diffuse aggressive polymorphous infiltrate / edema / hemorrhage / 
vasculitis I necrosis 
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Electrical stimulation of the heart. 
In the immediate postoperative period routine temporary epicardial atrial and 
ventricular electrodes were used in all patients. Further chronotropic support was 
provided by isoprotenerol-infusion. The heart rate was kept above 110 bpm during 
the first post-operative days. Depending on the hemodynamic condition the heart 
rate was allowed to decrease gradually below 100 bpm by lowering the electrical 
stimulation rate and the isoprotenerol dose. 
Statistics. 
For the determination of levels of statistical significance two sided p values using 
Fisher's Exact Test were calculated. 
4.4 Results 
The baseline characteristics of the 60 patients that were entered into this study are 
shown in Table 4.2. The BT563 group and the OKT3 group were comparable in 
respect to all of these characteristics. The majority of recipients were male (82%1, 
above 40 years of age (85%1 and suffered from ischemic heart disease (65%1. 
Most donors were below 40 years of age (83%1. Donors and recipients were not 
prospectively matched for CMV-serology. CMV positive donor / CMV negative 
recipient combinations were equally distributed among the two groups (Table 4.21. 
Within hours after the first gift of BT563 the IL-2R bearing cells (CD251 in 
peripheral blood were coated with the antibody. Peripheral blood lymphocytes 
remained negative for free CD25 molecules for the duration of BT563 adminstration 
and for a period of 1 to 12 days (median = 4 daysl thereafter. BT563 trough levels 
reached a plateau phase after day 4, with trough levels of 5300 (± 2001 ng/ml. The 
half life of BT563 in blood, calculated from the descending part of the curves, 
using a one-compartment model, was 39 ± 3 hrs. 
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Table 4.2 Baseline characteristics of heart transplant recipients 
Median age 
Median weight 
Gender (M/F) 
(range) 
(range) 
Underlying heart disease (n) 
ischemic 
cardiomyopathy 
valvular 
Median donor age (range) 
Mismatch -HLA-(n) A 
B 
DR 
CMV mismatch (ree-don + ) 
Cold ischemia time (min) median 
range 
Preoperative amiodarione treatment 
8T563 (n=31) 
53 (14-65) 
69(34-114) 
25/6 
20 
7 
4 
27 (14-45) 
1.3 
1.5 
1.5 
7 
155 
107-260 
11 
OKT3 (n =29) 
51 (24-65) 
63 (45-89) 
24/5 
19 
9 
1 
27 (12-44) 
1.2 
1.6 
1.5 
6 
152 
85-240 
4 
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In the OKT3 treated group the cytokine release syndrome occurred in the majority 
of patients (23/29 fever, 6/29 hypotension, 8/29 rash, 19/29 altered mental 
status). None of the 8T563 treated patients developed the typical cytokine release 
syndrome, although in some low·grade fever (10/31) and psychosyndrome (7/31) 
were found during the first postoperative days. Postoperative confusion after heart 
surgery is not unusual'o. Haloperidol, used to treat signs of organic 
psychosyndrome (mostly visual andlor auditory hallucinations), was given to 7/31 
(23%) of 8T563 and to 19/29 (66%) of OKT3 treated patients. 
In the 8T563-group two patients died, one as a result of hemorrhagic stroke on day 
4, the other due to sepsis after several thoracotomies for tamponade on day 17. 
These two patients were excluded from the analysis of rejection-incidence. Table 
4.3 and Figure 4.1 show the numbers of patients free from rejection at several 
intervals after transplantation. In the 8T563 group 13/29 (45 %) patients had their 
first rejection at week 1, whereas 15/29 (52 %) patients in the OKT3 group 
rejected between weeks 3 and 5. No differences between the two study groups 
were found for the total number of rejection episodes in the first year ( 2.8 vs 2.5 
for the 8T563 and OKT3 group respectively). Also no difference was found in the 
numbers of patients showing more than 2 rejection episodes (18/29 in 8T563 and 
15/29 in OKT3 recipients). At 3 months after transplantation freedom from 
rejection between the two groups was not significantly different. Treatment of the 
first rejection episode was successful with steroids in 15/25 (60 %) of 8T563 and 
16/24 (67 %) of OKT3 treated patients. The other 10/25 and 8/24 patients needed 
r A TG for refractory rejection. 
Table 2. Freedom from reJoclion 
Weeks after Tx 2 3 4 5 6 12 52 
BT563 16/29 15/29 12/29 10/29 9/29 7/29 5/29 5/29 
(n=29) (55%) (52%) (41%) (34%) (31%) (24%) (17%) (17%) 
OKr3 28/29 25/29 19/29 16/29 10/29 9/29 6/29 5/29 
(n=29) (97%) (86%) (66%) (55%) (34%) (31%) (21%) (17%) 
Table 4.3 Freedom from rejection after heart transplantation. 
60 
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o 1 2 3 4 5 6 12 52 
weeks after heart transplantation 
Figure 4.1 Freedom from rejection after heart transplantation, using induction 
immunosuppression with BT563 or OKT3. 
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Infectious complications within 90 days after transplantation are shown in Table 
4.4. Most infections were of minor clinical significance. The herpes hominis virus 
infections were labial infections (blisters). Urinary tract infections were mainly 
found in the first postoperative week, probably as a result of bladder 
catheterization. Of the 10 mild respiratory tract infections in the BT563 group 5 
occurred in two patients. 
Table 4.4 Infectious disease after heart transplantation (,; 90 days after tx) 
BT563 OKT3 
CMV disease 3 1 
Herpes Hominis Virus 7 14 
Urinary tract infections 7 7 
Respiratory tract infections 10 2 
Intracerebral toxoplasmosis 1 0 
Peridiverticular abces/perforation 2 0 
Other infections 5 3 
In the OKT3 group a mediastinal malignant lymphoma was diagnosed 5 months 
after transplantation in one patient, for which chemotherapy (CHOP) followed by 
radiotherapy was started, resulting in complete remission of the tumor and survival 
of the patient to date (now 32 months after transplantation). In another OKT3 
treated patient a metastasized bronchuscarcinoma was found 23 months after 
transplantation. He died 8 months later. 
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Although temporary pacemaker electrodes are routinely placed in all heart 
transplant recipients, we found differences in pacemaker support between the two 
groups. After excluding two patients (one patient in both groups) who needed a 
permanent pacemaker, and the two patients in the BT563 group that died in the 
post-operative period, the mean duration of pacemaker support in the BT563 group 
was 5.1 days and in the OKT3 group 2.1 days. Pacemaker support for more than 
three days was needed in 11/28(39%) of BT563 and 4/28 (14%) of OKT3 treated 
patients (p = 0.07). Although the difference did not reach statistical significance 
pre-operative amiodarone treatment was more frequent in the BT563 group (11/31) 
than in the OKT3 group (4/29) (p =0.07). Within the BT563 group pre-operative 
amiodarone treatment was also more prevalent in the patients needing pacemaker 
support for more than three days than in those who did not (7/11 vs 4117; 
p = 0.05). Of all patients needing pacemaker support for more than three days, only 
4 (4115) had an acute rejection in their first biopsy at week 1. 
4.5 Discussion 
In all patients receiving BT563 coating of all IL-2R positive cells was found in 
peripheral blood within one hour after the first gift. Coating persisted until 1 - 12 
days (median 4 days) after the last dose. Despite this clear effect of BT563 on 
peripheral blood lymphocytes, endomyocardial biopsies taken at the end of the 
prophylactic treatment period showed acute rejection in 13/29 patients. 
Immunohistochemistry of the biopsies demonstrated the presence of cells bearing 
uncoated IL-2Receptors within these endomyocardial biopsies during acute 
rejection" . 
The cytokine release syndrome, known to be associated with the use of OKT3, did 
not occur in the BT563 treated patients. Anti IL-2R MoAbs as a group appear to 
be free from this potential life-threatening side-effect"·'6. 
Freedom from rejection at 12 weeks after transplantation was not different 
between the OKT3 (6/29 = 21 %) and BT563 (5/29 = 17%) treated group. However, 
as is clearly demonstrated in Table 4.3 and Figure 4.1, the first acute rejection in 
the BT563 treated patients was often found in the first or second biopsy, whereas 
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most first acute rejection episodes in the OKT3 group occurred in weeks 3, 4 or 5. 
There was no difference in the severity of these rejections, as is shown by the 
similarity of required anti'rejection treatment courses. In both groups about two 
thirds of first acute rejections were steroid·responsive. All steroid-unresponsive 
rejections were treated with anti-T cell therapy (rabbit-ATG or OKT3). After the first 
rejection episode many patients experienced one or more subsequent acute 
rejections (Table 4.5). Cumulative numbers of rejections nor the required rejection 
treatments differed significantly between the groups. 
Table 4.5 Number of rejection episodes after heart transplantation. 
no. of rejections 
0- 1 
2-3 
>3 
BT563 
8 
11 
10 
OKT3 
10 
11 
8 
Infectious complications were not different between the two groups. Although 
many patients received anti T-cell therapy with ATG or OKT3 only four patients 
developed CMV disease, possibly because all CMV positive donor/CMV negative 
recipient combinations received prophylaxis with CMV hyperimmunoglobulins". 
The sample size of this study does not allow conclusions regarding malignancy 
induction, but it is remarkable that the two patients with malignancies both 
received OKT3-prophylaxis23 • 
The difference in duration of required electrical allograft stimulation cannot be 
explained by a difference in cold ischemia time between the two groups. Treatment 
with amiodarone prior to transplantation was more frequent in BT563 (11/31) 
compared to OKT3 recipients (4/29) (p = 0.07) and is the most likely explanation 
for the prolonged pacemaker support". No relation was found between prolonged 
pacemaker support and the occurrence of early acute rejection. The two permanent 
pacemakers were surgical complications, caused by intra-operative lesions and 
suturelines. 
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Although the low incidence of short and long term side effects observed are an 
advantage of BT563, the occurrence of early rejections in half of the BT563 treated 
patients is disappointing. A more favourable result with this monoclonal was 
obtained in a double-blind trial of rejection prophylaxis in renal transplant recipients, 
comparing a 10-day course of BT563 to placebo". In that trial a significant 
reduction of early acute rejections was found in the BT563 treated patients. Within 
the first 4 weeks after transplantation only 1/27 BT563 treated patients 
experienced an acute rejection, compared to 7/29 of the patients in the placebo-
group (p = 0.05). In contrast to the study presented here all renal allograft recipients 
had started cyclosporin on day O. In animal studies a synergistic effect of the 
combination of cyclosporin and anti IL-2R MoAbs has been demonstrated'. ". 
In our heart transplant recipients we started cyclosporin at day 3 after transplant 
in order to prevent renal insufficiency in the immediate postoperative period. One 
may hypothesize whether the results of rejection-prophylaxis with BT563 in these 
patients would have been better when cyclosporin had been initiated on the day 
of transplantation, thereby making optimal use of the synergistic effect of 
combining BT563 and cyclosporin. The results of our renal study support this 
hypothesis. 
In conclusion, the use of this anti IL-2R MoAb in heart transplant recipients was 
associated with less side effects than OKT3. The freedom from acute rejection in 
BT563 and OKT3 treated patients at 3 and 12 months was not significantly 
different. However, in BT563 treated patients the interval to the first rejection is 
shorter. 
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Chapter 5 
Intragraft monitoring of rejection following prophylactic treatment with monoclonal 
anti Interleukin·2Receptor antibody (BT563) in heart transplant recipients. 
This chapter is based on an article with the same title, published in The Journal of 
Heart and Lung Transplantation 1995; 14:346·350, by Gelder van T, Mulder AH, 
Balk AHMM, Mochtar B, Hesse CJ, Baan CC, Vaessen LMB, Weimar W. 
5.1 Abstract. 
In an open randomized study OKT3 and BT563, a murine IgG, anti IL-2R MoAb, 
were given as rejection prophylaxis during the first week after hearttransplantation. 
Cyclosporin therapy was initiated at the third postoperative day. In half of the 
BT563 treated patients an acute rejection was histologically demonstrated at week 
1, while OKT3 treated heart transplant recipients had a rejection-incidence at week 
1 of only 9%. In peripheral blood during BT563 treatment CD25-positive cells (i.e. 
cells bearing the IL-2R) were coated with the antibody. However, immunohistologic 
studies of endomyocardial biopsies taken one week after transplantation showed 
the presence of uncoated CD25-positive cells within these biopsies in 8/10 (80%) 
of rejecting patients. In patients without rejection uncoated CD25-positive cells 
were present in the biopsies of only 2/9 (22%) patients. RT-PCR-studies on biopsy-
material showed the presence of mRNA for the IL-2R in all, and for IL-2 in 3/5 
(60%) of biopsies of rejecting grafts. Other studies, in which anti IL-2R MoAbs and 
cyclosporin were simultaneously given from the start, did show a reduction in early 
rejection after organ transplantation. Our present results suggest that this 
synergistic effect can only be reached if anti IL-2R MoAbs are given in the presence 
of cyclosporin, thereby influencing different steps in the immune cascade. 
5.2 Introduction. 
Interleukin-2 (lL-2) and the IL-2Receptor (lL-2R) play an important role in the 
generation of a normal immune response 1, Therefore, it was a logic step to 
develop monoclonal antibodies (MoAbs) directed against the IL-2R in order to 
improve allograft survival'. Used as prophylaxis against early rejection these 
agents were considered to be valuable in kidney allograft recipients' 4. Anti IL-2R 
MoAbs have also been used succesfully in the prevention of rejection of cardiac 
allografts in several animal models' '. In November 1991 we started an open 
randomized, controlled trial of BT563 (a murine IgG, anti IL-2R MoAb, directed 
against the a-chain (p55) of the IL-2R) compared with murine monoclonal CD3 
antibody (OKT3) as rejection prophylaxis after heart transplantation. 
We report data of the monitoring of peripheral blood, BT563-levels, anti-BT563 
antibody formation, immunohistology and gene expression of IL-2 and IL-2R of 
endomyocardial biopsy (EMB) specimens and speculate on the possible causes of 
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the high rejection rate. 
5.3 Methods 
Cardiac allograft recipients were randomly assigned to receive prophylactic anti-
rejection treatment with BT563 or OKT3 after returning from surgery. BT563 
(Biotest Lab.- Dreieich Germany) was given in a dosage of 10 mg intravenously 
from day 0 to day 6 after transplantation. The control group received 5 mg OKT3 
according to the same protocol. In addition to BT563 or OKT3 from day 0 patients 
were treated with prednisone 50 mg daily, gradually decreased to 15 mg at 4 
weeks after transplantation. Cyclosporine was started at day 3 in a dosage of 8 
mg/kg/day, to achieve whole-blood levels of 400 to 500 ng/ml (radioimmunoassay). 
When the thrombocyte count was greater than 100 .109 cells/ml, 50 mg 
azathioprine was given for the first 6 postoperative days in an attempt to prevent 
the formation of anti-murine antibodies. EMB was performed weekly for the first 6 
weeks after transplantation. This study was approved by the Hospital Ethical 
Committee and informed consent was obtained from all patients. 
Peripheral blood monitoring. 
Before, during and after BT563 treatment peripheral blood samples were collected 
daily in EDTA containing tubes and monitored for the presence of T cell subsets by 
two color flow-cytometry using MoAb directly conjugated to fluorescein 
isothiocyanate (FITC) or phycoerythrin (PE). One hundred microliters whole blood 
was incubated with 20pl of the following dual MoAb combinations : CD45-
FITC/CD14-PE; IgG,-FITCllgG,,-PE as isotype controle; CD3-FITC/CD19-PE; CD3-
FITC/CD8-PE; CD3-FITC/CD4-PE; CD4-FITC/HLA-DR-PE, all obtained from 
Immunotech (Marseille, France); and the combination WT31-FITC(anti-
TCRa/B)/CD25-PE(MoAb 2A3) both obtained from Becton & Dickinson (San Jose, 
California, USA). After 30 minutes incubation at room temperature, red blood cells 
were lysed with FACS lysing solution (Becton & Dickinson) for 10 minutes. After 
washing, cells were analysed on a FACScan (B&D) flow-cytometer using SimulSet 
software (B&D) for data analysis. To establish an analysis gate that included at 
least 90% of the lymphocytes the CD45/CD14 reagent was used. One thousand 
to 2000 lymphocyte events were acquired from each tube. 
The CD25 MoAb 2A3 is also directed against the IL-2R a-chain, and is competitive 
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with BT563'. APE-conjugated polyclonal rat-antimouse antibody (RAM) (B&D) was 
used to determine whether CD25-positive cells in PBL were coated with BT563 
during treatment. 
Plasma BT563 levels. 
BT563 trough levels were measured daily during treatment. Plasma BT563 levels 
were determined with an ELISA sandwich method with goat antimouse-lgG 
(Southern Biological Associates, Birmingham, AL, USA) and alkaline-phosphatase-
(AP)-conjugated goat antimouse-lgG (H + L) antibodies (Jackson Immuno Research, 
West Grove, PA, USA). Plasma samples were diluted 1 :450 and 1 :2000 with a 
combination of tris(hydroxymethyl)aminomethane (TRIS)-buffered saline solution, 
polysorbate 20 (Tween 20), and bovine serum albumine (TBS/Tw/BSA). The 
concentration of BT563 was estimated by interpolation of obtained values on a 
standard curve of parental grade BT563 diluted in TBS/Tw/BSA. 
Anti BT563-antibodies. 
Anti BT563-antibodies were measured in an ELISA system with microtiterplates 
precoated with 0.1 ml BT563 solution ( 3 pg/ml, Phosphate Buffered Saline (PBS), 
pH 7.4). Plasma samples were initially diluted to 1 :50 and further in 0.1 ml double 
dilution steps. Human antibodies were detected with an AP-conjugated goat 
antihuman-lgG antibody (Jackson Immuno Research) and quantified by comparison 
with two different reference plasma samples. The concentration of antimouse-lgG 
antibodies in these reference plasmas was 54 and 154 pg/ml respectively. 
Pathology. 
A pathologist, unaware of the immunosuppressive protocol of the patient, 
examined EMB- specimens stained with hematoxylin-eosin by light microscopy. 
These biopsies were graded according to the criteria of the International Society for 
Heart and Lung Transplantations. Biopsies graded as 3A, 3B or 4 were regarded 
to represent acute rejection episodes necessitating antirejection treatment. 
Rejection was treated in the majority of cases with 1 gram methylprednisolon 
(Solu-Medrol) intravenously on three consecutive days. Refractory rejection was 
treated with rabbit-ATG. 
Snap-frozen EMB specimens were cut in 5 pm sections, air dried and fixed in 
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aceton. The slides were subsequently incubated with the appropriately diluted 
monoclonal antibody (CD3 = anti-Leu-4; CD4 = anti-Leu-3a; CD8 = anti-Leu-2a; 
CD25 = 2A3 (B&D)). The slides were rinsed in PBS and incubated with biotinylated 
antimouse-immunoglobulins (1 : 50 in PBS; Biogenex, San Ramon, California), rinsed 
and labeled with AP-Iabeled streptavidin (Biogenex, 1 :50 in PBS). The enzyme was 
finally detected with new fuchsin as a substrate as described by the manufacturer. 
The slides were examined and the number of positive staining cells was estimated. 
The results are expressed per half field at 100x magnification (obj. 1 OOx). A total 
field at this magnification measures 2.54 mm2 • Five groups were delineated: 0, 1-
10, 11-30,31-100 and more than 100 positive cells per half field (1.27mm2). 
RNA extraction and transcription. 
Snap-frozen EMB specimens, available from 11 patients, were homogenized using 
disposable micro pestles (Merck/Eppendorf) after which 104 mouse 3T3 cells 
(American Type Culture Collection, Rockville, Md.) were added to improve yield. 
Total RNA was extracted from snap-frozen EMB using a modified version of the 
guanidinium method described by Chomczynski and Sacchi'. After extraction, RNA 
was precipitated and dissolved in 50 pi diethylpolycarbonate treated water (DE PC-
H20). First-strand cDNA synthesis was performed at 42°C for 90 min using 25 pi 
ectracted RNA, 2.5 pi Moloney murine leukaemia virus (MMLV) reverse 
transcriptase (200 U/pl; Gibco-BRL, Gaithersburg, MD) and 0.25 pg 
hexanucleotides (0.5 pg/pl; Promega Corporation, Madison, WI) in a total reaction 
volume of 50 pl. 
PCR amplification and Southern Blot Analysis. 
Subsequently, 5 pi cDNA was amplified in a thermal cycler using 2 U Taq DNA 
polymerase (Promega) and 50 pmol of 3' and 5' human sequence specific primers 
(Clontech Laboratories, Palo Alto, Calif.). These primers were located next to splice 
sites, to allow discrimination for RNA only. PCR primers detecting transcripts for 
the human keratin gene (sense primer 5'TGAAGATCCGTGACTGGTAC3' and 
antisense primer 5' ATGTCGGCTTCCACACTCAT3') were used as an internal 
control to confirm succesful RNA extraction and cDNA amplification. The 
amplification temperatures and times were: 95°C for 5 minutes, followed by 40 
cycles with a 1 minute 95 DC denaturation, a 2 minute 60°C annealing of primers 
and a 3 minute 72 DC extension of primers. The last step was extended for 7 
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minutes. PCR products were electrophoresed on a 2% agarose gel in tris borate 
etylenediamnie tetra acetic acid, transferred to Hybond N + (Amersham, England) 
and hybridized with gamma32p end labeled internal probes, which are located across 
the splice-site (ll-2 and Il-2R a-chain: Clontech lab. and keratin: 
5'TGTCCTTCTGCAGA TTGACAATGCCCGTCT3'). Hybridization was detected by 
autoradiography. 
5.4 Results. 
Treatment with BT563 was not accompanied by side effects, in contrast to OKT3 
treatment, where the cytokine release syndrome (fever, confusion, hypotension) 
was seen in the majority (8/11) of patients. Before BT563 therapy was instituted 
10% to 25% of the PBls were positive for both the a and the B-chain of the Il-2R, 
as detected by the MoAb 2A3 and anti-ll-2RB respectively. After the first injection 
of BT563 PBls did not stain with 2A3, whereas a positive staining with rat 
antimouse antibody was found. The relative numbers of WT31/CD3, CD3/CD4, 
CD3/CD8 and CD3/HlA-DR positive cells did not change, indicating that the Il-2R 
had been coated by the antibody. This situation persisted during BT563 
administration and uncoated CD25-positive cells were not found in peripheral blood 
until at least 4 days after the last gift. In all patients in whom an acute rejection 
was shown in the biopsy specimen taken at the end of the BT563-treatment 
period, no uncoated CD25 positive cells could be detected in peripheral blood at 
the moment of rejection. BT563 levels were not significantly different between 
rejecting and non-rejecting patients (Table 5.1). At week 1 human antimouse 
antibodies (HAMA's) were found in only three of six nonrejecting and one of seven 
rejecting patients. 
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Table 1. Endomyocardlal biopsies In heart transplant recipients. 
Patient Pathology BT563 Immunohistochemistry mRNA IgM-
Initials Grade levels expression HAMA 
day 6 
CD3 CD4 CD8 C026 IL·2IL2R 
HA lA 6200 3 3 2 + 
II lA 5700 0 0 0 0 
FO lA 3900 NO ND NO ND + 
PE 0 5800 2 3 0 
VW 2 8100 0 0 
HU 0 6800 2 0 + + 
VF lA 4700 3 + 
VR 0 3600 3 0 + 
VS 0 8500 2 0 + 
60 0 6400 2 3 0 + 
DO lA 6200 ND ND ND ND + 
KN 3A 4200 2 2 0 
KE 3A 5600 ND ND ND NO + 
HR 3A 1700 3 3 3 2 
GO 3A 4300 2 3 
ST 3A 4200 3 3 
KA 3A 3700 3 2 2 + + 
8A 3A 6600 2 3 2 2 ND 
SO 3A 4700 2 3 2 2 + + 
GE 3A 8200 3 3 3 2 + 
8E 3A 6100 2 4 2 + 
RO 3A 6700 2 2 2 0 + + 
Table 5.1 Endomyocardial biopsies in heart transplant recipients. 
Legends. BT563 levels in ng/ml. Scoring of CD3, CD4. CD8 and CD25-positive 
cells according to numbers of cells per half field (obj. 1 OOx): 0 = 0 cells; 1 = 1-10 
cells; 2 = 11-30 cells; 3 = 31-100 cells; 4 = > 100 cells). IgM-HAMA : positive 
if a more than fourfold increase in IgM-HAMA was found within the first 10 days 
after transplantation. 
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Endomyocardial biopsies taken after 1 week of prophylactic treatment with ST563, 
using HE-light microscopic examination, showed acute rejection in 11/22 (50%) 
patients (all Grade 3A according to the criteria of the International Society for Heart 
and Lung Transplantation) was found (Table 5.1). Immunohistologic studies 
showed the presence of uncoated CD25-positive cells in these biopsies in eight of 
ten (80%) patients (Table 5.1). In the patients without rejection there were 
uncoated CD25-positive cells in the biopsies of only two of nine (22%) patients. 
Apart from CD25-positive cells intragraft presence of CD3, CD4 and CD8-positive 
cells was also correlated with the occurrence of acute rejection (Table 5.1). No 
significant differences between rejecting patients and non-rejecting patients existed 
for HLA-matching, body weight or cyclosporin-Ievels. In the control-group of OKT3 
treated patients at week 1 after transplantation the rejection incidence was one in 
eleven patients (9%). 
Reverse transcriptase PCR studies were performed on 11 snap-frozen and stored 
EMSs. Transcripts from the human keratin gene were amplified in all tested 
samples. mRNA extracted from the mouse 3T3 carrier cell line did not show 
expression of genes coding for human IL-2 and IL-2R or keratin. mRNA for IL-2R 
was found to be present in all samples, regardless of whether a rejection was 
present. mRNA for IL-2 could not be demonstrated in six non-rejection EMSs, but 
was found in three of five (60%) of rejection-EMSs (Table 5.1). 
5.5 Discussion. 
Prophylactic administration of ST563 in cardiac allograft recipients during the first 
week after transplantation resulted in coating of CD25 (i.e. IL-2R a-chain) on 
peripheral blood lymphocytes. Endomyocardial biopsies taken after this first week 
showed acute rejection in 11 of 22 (50%) of ST563-treated patients. Using 
immunohistologic techniques uncoated CD25-positive cells were found to be 
present in a high percentage (80%) of the rejecting patients (Table 5.1). Despite 
the effect of ST563 on peripheral blood, this prophylactic administration of ST563 
could not prevent intracardiallymphocyte activation and proliferation. PCR-studies 
on biopsy material also showed the presence of mRNA for the IL-2R in all, and for 
IL-2 in three of five (60%) biopsies of rejecting grafts (Table 5.1). We have 
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previously shown IL-2 gene expression in relation to acute cardiac rejection '0. 
It is remarkable that we still found rejection of the graft even though results from 
peripheral blood looked so promising. As is clear from Table 5.1 the BT563 blood 
levels did not differ between rejecting and non-rejecting patients. Neither can 
HAMA-formation explain the difference between the 2 groups. Lymphocyte 
activation and proliferation in the graft nevertheless did occur and may have been 
the result of low intragraft BT563 levels. Alternatively lymphocyte activation may 
have taken place through non-IL-2R dependent pathways, resulting in a rejection-
incidence of 50%. 
In a prospective, double-blind, randomized, placebo-controlled study on the safety 
and efficacy of BT563 as rejection-prophylaxis in kidney transplantation we have 
found a significant effect of BT563 in the prevention of early rejection episodes ". 
Patients were treated with BT563 or placebo for the first 10 days, while 
cyclosporin was started six hours post-transplantation. In the present heart-
transplantation study cyclosporin was started at the third post-operative day, in 
order to avoid the nephrotoxic effects of cyclosporine in the first post-operative 
days. Cyclosporin inhibits the expression of IL-2 at the transcriptionallevel 12, and 
possibly of the IL-2R as well'3. In animal studies a synergistic effect of 
cyclosporin and anti IL-2R MoAbs has been demonstrated, probably as the net 
result of influencing different steps in the immune cascade" 16. In view of the 
significant effect on rejection prophylaxis found in the kidney and liver'· 
transplantation studies, it may be that clinical rejection can be prevented only when 
anti IL-2R MoAb therapy is given in the presence of cyclosporin. 
In summary, at week 1 after transplantation we have found a high incidence of 
rejection in heart transplant recipients who were prophylactically treated with 
BT563. Despite a clear effect of BT563 on peripheral blood, with coating of all IL-
2R bearing cells, a considerable number of CD25-positive cells was found to be 
present within the grafts. An activated state of the IL-2 & IL-2R pathway was also 
shown with reverse transcriptase PCR-techniques. We postulate that the high 
failure rate of this prophylaxis is at least partly due to the fact that cyclosporin was 
only started at day 3 after transplantation, thereby missing the synergistic effect 
of combining anti IL-2R MoAb and cyclosporin. 
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Chapter 6 
A double-blind, placebo-controlled study of monoclonal anti Interleukin-2Receptor 
antibody (BT563) administration to prevent acute rejection after kidney 
transplantation. 
This chapter is based on an article with the same title, published in Transplantation 
1995;60:248-252, by Gelder van T. Zietse R, Mulder AH, Yzermans JNM, Hesse 
CJ, Vaessen LMB, Weimar W. 
6.1 Summary 
In a double blind, randomized, placebo-controlled trial BT563, a murine IgG, anti-
Interleukin-2Receptor antibody, was given as a rejection prophylaxis after kidney 
transplantation. Drug related side effects were not observed. During the 10-day 
course of BT563 no rejections (0/27) were found, whereas a rejection episode 
occurred in 7 patients (7/29) (p ~ 0.01) during placebo treatment. Within the first 
4 post-operative weeks freedom from rejection in the BT563 group and in the 
placebo-group was 96% vs 76% (p~0.05). Due to rejection in the placebo-group 
2 grafts were lost. At three months an overall rejection-incidence in the BT563 and 
placebo-group was found of 3/27 (11 %) vs 8/29 (28%) (p ~0.18). Infectious 
complications were distributed equally between the 2 groups. CMV-disease, found 
in 3 placebo-treated patients, occurred after rejection-treatment (2/3). Within the 
BT563 group one patient lost his graft due to renal artery thrombosis, two grafts 
were lost as a result of technical failure and two patients had a squamous cell 
carcinoma that could be treated curatively. We conclude that the use of the anti 
IL-2R MoAb BT563 effectively prevents rejection after kidney transplantation 
without increasing infectious complications. 
6.2 Introduction. 
Interleukin-2 (IL-2) is a key cytokine in the generation and regulation of the immune 
response'. It is produced by activated T-cells and induces proliferation and 
differentiation of T- and B-Iymphocytes. IL-2 is one of the strongest amplifiers of 
T-cell activation leading to acute cellular allograft rejection'. Resting T-cells 
express neither the a (p55) low-affinity component of the IL-2Receptor (IL-2R) nor 
the functional high-affinity IL-2R. Following antigenic stimulation through the T-cell 
receptor, specific T-cells are activated, IL-2 is secreted, and functional IL-2R is 
transiently expressed, allowing antigen-committed lymphocytes to expand'. The 
clinical use of IL-2R antagonists after transplantation may therefore result in a 
selective blockade of T-cell activation, thereby preventing rejection. Thus it may 
provide an elegant alternative to the anti pan-T-cell antibody preparations like the 
monoclonal antibody OKT3 and polyclonal antithymocyte and antilymphocyte 
globuline preparations, that react indiscriminately with both activated and resting 
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T-cells'. Overimmunosuppression, inherent to their usage, is reflected in the 
induction of infections and malignancies. In contrast to these aselective agents anti 
IL-2R antibodies may not be associated with increased risks of infections or 
malignancies. After having been used as a treatment for graft-versus-host disease 
in bone marrow transplantation', anti IL-2R monoclonal antibodies (MoAb) have 
been given as rejection-prophylaxis after kidney'78, combined kidney/pancreas9 
and Iiver,01112 transplantation. It has been suggested that their efficacy was 
comparable to that of polyclonal anti T-cell preparations'12. Disappointingly in the 
only available placebo-controlled study no beneficial effect of anti IL-2R antibody 
prophylaxis was observed after liver transplantation'o. Monoclonal anti IL-2R 
antibodies may however differ vastly in their biological activity, due to differences 
in epitope recognition, affinity, isotype etc. 
We have performed a double-blind, placebo-controlled study to prevent rejection 
after kidney transplantation, with an anti IL-2R antibody (BT563), that in vitro 
showed high efficacy in blocking the mixed lymphocyte reaction 13. 
6.3 Material and Methods 
BT563 is a murine antibody of the IgG,-kappa isotype, directed against the p55-
chain of the IL-2R complex. It was previously known as B-B1 0 and was developed 
and produced by Wijdenes in Besancon'. It is currently being produced by Biotest 
Pharma, Dreieich, Germany. 
Patients 
From March 1992 through August 1993 60 first renal allograft recipients were 
randomized for treatment with either BT563 or placebo. The study was approved 
by the Hospital Ethical Committee and written informed consent was obtained prior 
to randomization. All patients received pretransplant blood transfusions and had 
negative crossmatches with their donors in historical and current sera. Baseline 
characteristics of the patients are given in Table 6.1. The causes of end-stage renal 
failure were comparable. For all patients the 1-year follow-up results are shown. 
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Table 6.1. Base·llne characteristics of kidney allograft recipients. 
Placebo BT563 
n = 30 n - 30 
age (yrs) • median (range) 45 (19·65) 43 (22·60) 
sex M/F 19 I 11 18 I 12 
race - Caucasian/other 25 I 5 27 I 3 
weight (kg) . median (range) 75 (50·120) 68 (54·95) 
dialysis prior to tx . CIHD 16 19 
. CAPO 8 9 
- none 6 2 
cadaver donor/living related 22 I 8 25 I 5 
donor age (yr) . median (range) 37 (12·64) 50 (15·71) 
donor sex· M/F 18 I 12 16 I 14 
mean no. mismatches HLA- 0.9 I 0.6 I 0.4 0.9 I 0.9 I 0.5 
A/B/DR 
Panel Reactive Antibodies 26 26 
«10%) 
Cold Ischemia Time - median 
(range) 
26 (12·37) 27 (13·36) 
Immunosuppression 
Two hours after surgery patients received two numbered ampules intravenously, 
each containing 5ml of either BT563 (1 mg/ml) or placebo (NaGI 0.9%). The next 
morning they received another 10 ml and this was continued for the first ten post· 
operative days. Gyclosporine (GsA) was given at a dose of 2 mg/kg/day Lv. until 
day 3, and at 8 mg/kg/day orally thereafter. Dosage adjustments were made aiming 
at a whole blood GsA·level of 300 ng/ml for the first 3 months. Prednisone was 
tapered from a dosage of 50 mg Lv. in the first 2 days to 15 mg orally from day 
3. 
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Peripheral blood monitoring for T-cells. 
Venous blood samples were obtained before transplantation, daily during the first 
14 post-operative days, and twice weekly thereafter, until 1 month after 
transplantation, to monitor the presence of T cell subsets by two color flow 
cytometry using MoAb directly conjugated to fluorescein (FITC) or phycoerythrin 
(PEl. 
Whole blood (100pl) was added to Falcon 2052 tubes (Becton & Dickinson, Lincoln 
Park, New Jersey, USA), washed twice with 2 ml phosphate buffered saline, to 
remove BT563 and human anti-mouse antibodies that might interfere with the 
staining procedures. After the cells were pelleted by centrifugation, 20 pi of the 
following dual MoAb combinations were added: CD45-FITC/CD14-PE; IgG1-
FITC/lgG2a-PE as isotype control; CD3-FITC/CD19-PE; CD3-FITC/CD8-PE; CD3-
FITC/CD4-PE; CD3-FITC/HLA-DR-PE (all from Immunotech, Marseille, France); and 
the combination anti-TCRaB-FITC(clone WT31)/CD25-PE(clone2A3) (both from 
B&D, San Jose, California, USA). For the detection of CD122 (the IL-2RB-chain 
(p75)) the cells were stained with 20 pi of the FITC conjugated MoAb TIC-1 
(Endogen, Boston, USA). To screen for BT563 bound to T-cells because of 
treatment, 5 pi of a PE conjugated polyclonal Rat-anti-mouse (RAM) (B&D) was 
added to washed and unwashed whole blood cells. Both anti-CD122 and RAM 
were used in combination with CD3-FITC. After 30 minutes of incubation at room 
temperature, red blood cells were lysed with FACS lysing solution (B&D) during 10 
minutes. After they were washed with sheet-fluid Cellpack (TOA Medical 
Electronics, Kobe, Japan) cells were analysed on a FACScan flowcytometer (B&D) 
using SimulSet software (B&D) for data analysis. To establish an analysis gate that 
included 95% lymphocytes, the CD45/CD14 reagent was used. From each tube 
1000-2000 lymphocyte events were acquired. For the detection of free binding 
sites on the IL-2R (CD25) positive cells the MoAb 2A3 is suitable, since, like 
BT563, 2A3 is directed against the IL-2Ra-chain, and recognizes an epitope of the 
same cluster on the p55-chain 13• Total white blood cell count was performed on a 
Sysmex microcell counter (TOA) after lysing the red blood cells with Quicklyser 
QL Y-200A (TOA). 
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Monitoring for BT563. 
Plasma BT563 levels were determined with an ELISA sandwich method using goat 
antimouse-lgG (Southern Biological Associates, Birmingham, AL, USA) and alkaline 
phosphatase-(AP)-conjugated antimouse-lgG (H + L) antibodies (Jackson Immuno 
Research, West Grove, PA,USA). Wells were filled with 8 serial dilutions of human 
plasma samples or reference samples, starting at a 1 :50 dilution, and quantified by 
comparison of calculated regression lines with those of two different reference 
plasma samples. 
Human Anti-Mouse Antibodies. 
Anti-BT563 antibodies were detected in an ELISA system using microtiterplates 
precoated with BT563. Human antibodies were detected with an AP-conjugated 
goat antihuman-lgG antibody or goat antihuman-lgM (Jackson) and quantified by 
comparison with two different reference plasma samples. The concentration of anti-
mouse-lgG antibodies in these reference plasmas was 54 and 154 mgtl 
respectively. For IgM antibodies an arbitrary Unit was defined. 
The physicians on the Transplantation Department and the physician collecting all 
clinical data (TvG) were blinded for the results of peripheral blood monitoring, 
BT563 levels and antibody-levels. 
Rejection-monitoring. 
The diagnosis of acute rejection was made on clinical grounds by the responsible 
nephrologist, and was confirmed by core needle biopsy. Clinical indicators of acute 
rejection included rising creatinine, oliguria, fever and graft tenderness, in the 
absence of mechanical causes of renal dysfunction or toxic CsA-levels. Acute 
rejections were treated initially with 1 gram Lv. of methylprednisolone (Solu-
Medrol, Upjohn) on three consecutive days. Steroid-resistant rejections were 
treated with rabbit-antithymocyte globuline (r-ATG). If an acute rejection occurred 
and anti-rejection therapy had to be started within the first ten post-operative days 
the study-treatment was continued. 
For statistical analysis the two-tailed Fisher's Exact Test was used. 
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6.4 Results 
BT563 tolerance. 
The anti IL-2R antibody BT563 was tolerated remarkably well. Its use was not 
accompanied by the cytokine release syndrome, consisting of fever, hypotension 
and confusion, and treatment did not have to be discontinued in any patient for 
clinical intolerance. Only one BT563 treated patient experienced severe nausea with 
vomiting during six days, whereas in the placebo-group one patient temporarily 
complained of arthralgia, rash and low-grade fever. 
Peripheral blood monitoringl BT563 levelsl antiBT563 antibodies. 
In the placebo group no changes in the proportions of CD3, CD4, CD8 and CD25-
positive cell populations were observed. Within one day after the first injection of 
BT563, free binding sites on CD25 positive cells were no longer detectable in 
peripheral blood, using the MoAb 2A3, whereas CD3, CD4 and CD8 positive cells 
remained present in constant relative numbers. Staining with Rat-anti-Mouse 
antibody showed coating of all CD25 positive cells. Using labeled 2A3, no free 
binding sites on the IL-2R could be detected. After the last dose of BT563, CD25 
remained coated with the antibody during a period of several weeks (median ~ 14 
days; range ~ 3-26 days). CD25 always appeared at once on 20 - 25% of T cells, 
without an increase in the absolute number of CD3 positive cells. This is also 
indicative of coating of the CD25 molecule from activated T cells rather than 
elimination of cells from the circulation as seen during treatment with OKT3 14• 
BT563 trough levels reached a' plateau phase after day 4. The mean trough level 
at day 9 was 5.14 ± 0.40 jlg/ml. The mean T% for this monoclonal was 42 ± 5 
hrs. A more than 4-fold increase from baseline in human anti-mouse antibodies 
(HAMAs) was found in 13/28 (46%) patients for IgM and in 4/28 (14%) patients 
for IgG. This increase in IgM-HAMAs was reached in the third and fourth week 
post-transplant in 85% of patients. In 5/13 the HAMA-response coincided with 
disappearance of BT563 from peripheral blod, in 6/1 3 patients this occurred at least 
1 week after disappearance of BT563, wheras in 2/13 patients this occurred just 
before BT563-clearance. 
Acute Tubulus Necrosisl (Delayed) Graft Function. 
In both groups a relatively small number of patients needed temporary renal 
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replacement therapy for delayed graft function (7/30 and 5127 for placebo and 
BT563-treated patients respectively). The duration of dialysis requirement was not 
statistically different between the two groups (placebo: mean = 17 days (range = 4-
31); BT563: mean= 10 days (range=2-19)). At 1-year follow-up median serum 
creatinine levels were not significantly different (placebo: median = 141f1mol/l 
(range = 74-328); BT563: median = 157f1molll (range = 87-305)). 
Rejection incidence. 
In 7 patients in the placebo-group a rejection occurred during the first 10 post-
operative days. Treatment with steroids resulted in reversal of this rejection episode 
in 4/7 patients. In the other 3 patients the rejection was steroid-resistant and a 
subsequent course of r-ATG had to be given, which was successful in only 1 
patient. In the other 2 patients the rejection resulted in graft loss. In the BT563-
group no rejection episodes were diagnosed during the prophylactic treatment 
period (p=0.011; see Table 6.2). Within the first 4 post-operative weeks in the 
BT563-group only 1 steroid-responsive rejection occurred. In the subsequent 8 
weeks 1 rejection episode occurred in the placebo-group and 2 occurred in the 
BT563-group. Thereafter a short course of methylprednisolon proved to be 
neccessary both in a BT563 and in a placebo-treated patient after conversion from 
cyclosporin to azathioprine medication at 6 months after transplantation. Actual 
freedom from rejection at one year in the patients at risk was 85 % in the BT563-
group and 68% in the placebo-group. 
Table 6.2 
Patients with acute rejection after kidney transplantation 
Days after tx Placebo BT563 g·value* 
0- 10 7/29 0/27 p =0.011 
0-28 7/29 1/27 p=0.052 
0-90 8/29 3/27 p=0.181 
0-365 9/28 4/27 p=0.205 
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Infectious complications. 
Table 6.3 shows the infectious complications. No significant differences between 
the two groups were found. In 2 placebo-treated patients CMV-disease followed 
rejection treatment with steroids andlor r-ATG. One BT563 treated patient 
experiencing a primary EBV-infection underwent tracheostomy because of a large 
pharyngeal lymphomatous swelling, which disappeared after tapering of the CsA 
dosage". 
Tabl.6.3 Infectious complications after kidney transplantation. 
week 0 - 4 week 5 - 12 
Type of infection placebo BT563 placebo BT563 
n = 29 n = 27 n = 28 n = 27 
Bacterial 
urinary tract infection 8 8 4 8 
pneumonia 0 0 0 
perirenal infection 0 0 
endocarditis lenta 0 0 0 
S. au reus sepsis 0 0 
Viral 
CMV - disease 0 0 3 0 
herpes genitalis 0 0 0 
herpes zoster 0 0 0 
primary EBV - infection 0 0 0 
Fungal 
Candida albicans stomatitis 0 1 0 0 
Candida albicans peritonitis 0 0 0 
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Graft and patient survival. 
Two grafts were lost within the first 5 postoperative days due to technical failure 
(difficult vascular anastomosis and torsion of vessels) and another graft was lost 
due to renal artery thrombosis (all three in the BT563 group). At 6 months and at 
11 months two patients in th BT563 group lost their grafts due to chronic rejection. 
In the placebo group two patients lost their graft due to acute rejection, one of 
them died three months later from uremia and sepsis. One placebo-treated patient 
suffered from a non-fatal myocardial infarction on the second post-operative day; 
4 months later he was resuscitated outside the hospital and died a few days later. 
Acute necrotizing pancreatitis developed in another placebo-treated patient at day 
4; this patient was removed from the study and died at day 32. Actual overall one 
year graft survival was 84% for the BT563 patients and 87% for the placebo-
group. Patient survival at 1 year was 100% in the BT563 and 90% in the placebo 
group. 
Other complications. 
A spontaneously resolving ileus lasting 1 week occurred in a placebo-treated 
patient immediately after transplantation. One BT563 treated patient was found to 
have Menetrier's disease two months after transplantation. Two other patients in 
the BT563 group had a squamous cell carcinoma (one localized in the pharynx, 
detected three months after transplantation, and one on the skin of the lower leg, 
diagnosed eight months after transplantation). Both tumors were treated radically. 
6.5 Discussion. 
This randomized prospective trial is the first to investigate the efficacy and safety 
of an anti IL-2R MoAb in the prevention of kidney allograft rejection in a double-
blind fashion. It shows a beneficial effect of BT563 in the prevention of early 
rejection after kidney transplantation. At 12 weeks the difference between the two 
groups is 3 vs. 8 patients with a rejection (Figure 6.1) and 2 graft losses due to 
rejection in the placebo-group. At 1-year follow-up the overall graft and patient 
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survival in the BT563 and placebo group were 84% vs 87% and 100% and 90%. 
As is shown in Table 6.3 the applied use of BT563 did not result in a higher 
incidence of infectious complications. CMV infections were more frequent in the 
placebo-group, probably due to the required use of rejection-treatment in this 
group. In contrast to the infectious complications there was an unfortunate 
occurrence of two squamous cell carcinomas in the BT563-group, but these were 
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treated curatively and did not lead to death. Drug related side effects were not 
observed. Unexpected was the occurrence of renal artery thrombosis in one BT563 
treated patient. Vascular thrombosis is a well known complication of the use of 
mono- and polyclonal anti pan-T-cell preparations" ". It is unclear whether this 
is also the case for anti IL-2R MoAbs, for which this has not been reported before. 
In 1990 Soulillou et al published the results of a study· comparing 33B3. 1 (another 
anti IL-2R MoAb) with r-ATG for rejection prophylaxis in kidney transplantation. In 
this study a rejection occurred in 6/49 patients (12%1 during the 14-day course of 
33B3.1, whereas in our study no BT563 treated patient had a rejection during the 
prophylactic treatment. In our study during the treatment-phase CD25 + cells in 
peripheral blood were coated, and free binding sites on the IL-2R returned only after 
a median of 14 days after this 10-day course. Soulillou described that uncoated 
CD25 + cells returned during the 3383.1 course. The most likely explanation for 
this difference is the fact that in the latter study cyclosporin was started on day 14 
(at the end of the MoAb-administration), whereas in our study cyclosporin was 
started on day O. Cyclosporin inhibits the expression of IL-2 at the transcriptional 
level'·, but only partially inhibits the synthesis of the IL-2R'9. In animal studies 
a synergistic effect of combining cyclosporin and anti IL-2R MoAbs has been 
demonstrated, which probably is the result of influencing different steps in the 
immune cascade20 21. 
In the study by Kirkman et al7 .rejection episodes also occurred during treatment 
with the anti IL-2R MoAb anti-Tac (5/40). Cyclosporin in this study was started on 
day O. In contrast to the 33B3.1 and our study, uncoated CD25 + cells remained 
present in peripheral blood throughout treatment, reflecting the limited potency of 
anti-Tac MoAb. The differences in efficacy between several anti IL-2R MoAbs may 
be due to affinity and binding of the MoAbs to different epitopes of the IL-2R. 
In conclusion the use of BT563 in combination with cyclosporin is effective in 
preventing acute rejection after kidney transplantation without being associated 
with a higher incidence of infectious complications. In view of the two squamous 
cell carcinomas in the BT563 group this must be carefully followed in future trials. 
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Chapter 7 
Reversal of heart allograft rejection with monoclonal anti-interleukin-2 receptor 
antibody_ 
This chapter has been published in abstract form as a Letter, entitled "Reversal of 
graft rejection with monoclonal anti-interleukin-2 receptor", in The Lancet 
1992;339:873 by Gelder van "0 8alk AHMM Mochtar B, Weimar W. 
7.1 Introduction 
Since 1987 monoclonal antibodies (MoAb) to the interleukin-2 receptor (lL-2R) have 
been used in clinical organ transplantation'. Although some preparations were 
shown to be effective in the prevention of rejection after kidney' and Iiver3 
transplantation, their efficacy in rejection treatment is still speculative'. In heart 
transplantation in animals, anti IL-2R MoAbs were effective both in prevention' 
and treatment" of rejection. We report succesful treatment with BT563, a murine 
IgG, anti IL-2R MoAb, in three heart transplant recipients with acute graft rejection. 
7.2 Patients and methods 
Two men and one woman (ages 57, 58 and 59 years respectively) underwent heart 
transplantation in the first half of 1991 because of end-stage heart failure due to 
dilated cardiomyopathy. Maintenance immunosuppression consisted of cyclosporin 
and prednisone. After transplantation they experienced several rejection episodes, 
for which they received pulsed doses of methylprednisolone, OKT3 and rabbit 
antithymocyte globulin (RIVM, Bilthoven, The Netherlands!. An overview of the 
clinical characteristics of these three patients is given in Table 7.1. All three 
patients had a recurrence of rejection graded 3A (Figure 7.1), according to the 
criteria of the International Society for Heart Transplantation'. The episodes under 
study (fourth or fifth rejection episode respectively) were treated with BT563 (10 
mg intravenously for 10 days in one patient; 5 mg iv for 10 days in the two 
others). 
96 
A 
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Figure 7.1 Microscopy of heart allograft endomyocardial biopsies, showing (A) 
no rejection (grade 0), and (6) multifocal aggressive infiltrates with myocyte 
damage (grade 3A). 
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Table 7.1 Clinical characteristics of 3 heart allograft recipients. 
patient 1 patient 2 patient 3 
age 57 59 58 
sex M F M 
heart disease dilated CMP dilated CMP dilated CMP 
panel reactive antibodies 4% 96% 0% 
date of transplant 18.03.1991 15.06.1991 28.05.1991 
HLA mismatches AlB/Dr 2/2/1 2/1/2 1/1/1 
current rejection date 06.01.1992 31.10.1991 17.12.1991 
grade 3A 3A 3A 
rejection episode 5th 4th 5th 
daily dose BT563 5 mg 10 mg 5 mg 
7.3 Results 
Treatment with BT563 in these three heart transplant recipients did not result in 
any clinically significant side-effect. After the first dose of BT563 all CD25 positive 
cells in peripheral blood were coated with the anitbody, in both patients treated 
with a daily dose of 5 mg as well as in the patient treated with 10mg daily. Trough 
levels reached 3500 ng/ml in the 5 mg treated patients and 9500 ng/ml in the 
patient receiving 10 mg daily. Twelve days after the last dose of BT563 a control 
endomyocardial biopsy was taken from all three patients, showing grade 1 A in one 
patient and grade 0 in the other two. 
7.4 Discussion 
Analysis of the cellular infiltrate present in rejecting cardiac allografts has shown 
an accummulation of large numbers of donor-specific cytotoxic T-Iymphocytes, 
correlated with extensive inflammatory endothelial development and myocyte 
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destructions. Interleukin-2 produced by these CD4 positive T-cells directly 
promotes their proliferation and promotes the production of other cytokines like 
interferon·y, contributing to the development of inflammation. IL-2R directed 
therapy may interrupt the rejection cascade. 
Early experience with BT563 in the treatment of rejection was obtained in the 
succesful treatment of acute graft-versus-host disease (GVHD), refractory to 
corticosteroids'. 
The three patients described in this paper had already been treated with OKT3, 
ATG and Solu·Medrol for previous rejection-episodes. During and after treatment 
of rejection sensitization to OKT3 and ATG may have occurred, potentially leading 
to serum sickness when retreated with these agents. Even worse, sensitization to 
OKT3 has been related to the development of vascular rejection in cardiac allograft 
recipients leading to increased graft loss'o. Therefore the decision was made to 
treat this rejection episode with BT563. The administration of BT563, similar to 
patients receiving this drug for rejection·prophylaxis, did not result in any adverse 
side·effect and monitoring of peripheral blood showed coating of CD25 positive 
cells. 
Control endomyocardial biopsies in all 3 patients showed resolved rejection (biopsy 
grades 0 or 1A). We therefore conclude that BT563 is a safe and efficacious drug 
in the treatment of acute rejection in heart allograft recipients. 
99 
7.5 References 
1. Kupiec-Weglinski JW, Diamantstein T, Tilney N. Interleukin 2 receptor 
targeted therapy: rationale and applications in organ transplantation. 
Transplantation 1988;46:785-792. 
2. Soulillou JP, Peyronnet P, LeMauff B, et al. Prevention of rejection of kidney 
transplants by monoclonal antibody directed against interleukin 2. Lancet 
1987;i:339-342. 
3. Otto G, Thies J, Manner M, et al. Monoclonal antibody to interleukin-2 
receptor in liver graft rejection. Lancet 1990;335: 1596-1597. 
4. Cantarovich 0, LeMauff B, Hourmant M, et al. Anti-interleukin 2 receptor 
monoclonal antibody in the treatment of ongoing acute rejection episodes of 
human kidney graft - a pilot study. Transplantation 1989;47:454-457. 
5. Kirkman RI, Barrett LV, Gaulton GN, et al. The effect of anti interleukin-2 
receptor monoclonal antibody on allograft rejection. Transplantation 
1985;40:719-722. 
6. Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB. Therapy with 
monoclonal antibody to interleukin 2 receptor spares suppressor T cells and 
prevents or reverses acute allograft rejection in rats. Proc Nail Acad Sci USA 
1986;83:2624-2627. 
7. Billingham ME, Cary NRB, Hammond ME, et al. A working formulation for the 
standardization of nomenclature in the diagnosis of heart and lung rejection: 
heart rejection study group. J Heart Transpl 1990;9:587-593. 
8. Bishop OK, Shelby J, Eichwald EJ. Mobilization of T lymphocytes following 
cardiac transplantation. Transplantation 1992;53:849-857. 
9. Herve P, Wijdenes J, Bergerat JP, Milpied N, Gaud C, Bordigoni P. Treatment 
of acute graft-versus-hostdisease with monoclonal antibody to IL-2Receptor. 
Lancet 1988;ii: 1 072-1 073. 
10. Hammond EH, Wittwer CT, Greenwood J, Knape WA, Yowell RL, Menlove 
RL, Craven C, Renlund DG, Bristow MR, DeWitt CW, O'Connell JB. 
Relationship of OKT3 sensitization and vascular rejection in cardiac 
transplant patients receiving OKT3 rejection prophylaxis. Transplantation 
1990;50:776-782. 
100 
Chapter 8 
Summary and conclusions. 
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8.1 Summary and conclusions. 
Monoclonal and polyclonal antibody preparations have been used for induction 
therapy after organ transplantation. Apart from serious side effects directly 
associated with their use, e.g. the cytokine release syndrome, the resulting deep 
and aspecific immunosuppression leads to increased incidences of infections and 
in the long term of malignancies. To avoid the drawbacks of this aselective 
immunosuppression monoclonal antibodies against specific T-cell activation 
determinants have been developed. In view of the pivotal role of Interleukin-2 in 
the activation cascade of antigen-stimulated lymphocytes, monoclonals directed 
against the Interleukin-2Receptor were thought to have a strong inhibitory effect 
on activated T-Iymphocytes only. 
We have performed in vitro studies using several different anti IL-2R monoclonals 
because not all anti IL-2R mAb are equally effective. Depending on the epitope 
recognized, the affinity of the mAb, type of F ,-receptor, the resulting human anti-
mouse antibody response and the T1I, of the mAb, the in vivo efficacy may vary. 
For some mAbs the results of in vitro experiments seem to be reflected in 
immunosuppressive potential. In vitro experiments with anti-Tac, in comparison 
with 8T563 and 3383.1, showed only limited potency of anti-Tac in inhibiting 
mixed lymphocyte reactions. 8T563 was able to strongly inhibit lymphocyte 
activation in concentrations that can easily be reached in a clinical setting. A pilot 
study in 12 renal transplant recipients showed excellent tolerance, serum levels 
that in vitro were efficacious and coating with the antibody of all CD25 positive 
cells in peripheral blood during prophylactic 8T563 treatment. None of these 12 
patients showed signs of rejection. 
This made 8T563 an attractive and promising drug and in 1991 we started two 
large clinical trials with 8T563 as a prophylaxis against rejection after solid organ 
transplantation. 
Sixty first and second renal transplant recipients were randomized for double-blind 
prophylactic treatment with either placebo or 8T563 during the first 10 days after 
transplantation. From day 0 all patients received prednisone and cyclosporin as 
maintenance treatment. Drug related side effects were not observed. During the 
10-day course of 8T563 no rejections were found, whereas during placebo-
treatment in 7/29 patients an acute rejection occurred (p=0.01). At 4 weeks after 
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transplantation freedom from rejection in the BTS63 and placebo-group were 96% 
and 76% respectively (p=O.OS). Due to rejection in the placebo-group 2 grafts were 
lost. Infectious complications were equally distributed between the two groups. It 
was concluded that BTS63 effectively prevents rejection after kidney 
transplantation and does not lead to drug-related side-effects or to an increased 
incidence of infections. 
The other study was performed in 60 heart transplant recipients, who were 
randomized for a 7 -day course of either BTS63 or OKT3 as rejection-prophylaxis. 
These patients also had prednisone and cyclosporin as maintenance treatment, 
but cyclosporin here was started on day 3. In the first week the majority (27/29) of 
OKT3 treated patients suffered from one or more symptoms of the cytokine 
release syndrome (fever, hypotension, psychosyndrome, rash). In some (13/31) of 
the BTS63 treated patients low-grade fever and mild confusion were found, but 
these were not life-threatening and are often seen following open heart surgery. 
First acute rejections in the BTS63 group were often found in the first or second 
week (14/29=48%), whereas first acute rejections in the OKT3 group usually 
occurred a little later (in weeks 3, 4 or S: 1S/29=S2%). However, at 3 months after 
transplantation freedom from acute rejection between the two groups was not 
significantly different ( 17 vs 21%). Neither was there a difference in the amount of 
steroids or anti T-cell treatments (OKT3/ATG) used for rejection-treatment. 
Infectious complications were equally distributed in both groups. The early 
rejections in the BTS63 group at week 1 occurred after one week of treatment, in 
the presence of seemingly adequate concentrations of BTS63 in the circulation 
and in a situation of complete CD2S-coating in peripheral blood. To see whether 
uncoated CD2S-positive cells could be found within the rejecting grafts 
immunohistologic studies on the week 1-biopsies were done. In 80% of the 
rejecting patients uncoated CD2S-positive cells were present within the 
endomyocardial biopsies, whereas these cells could be detected in only 22% of 
non-rejecting grafts. RT-PCR studies on a limited number of biopsies showed the 
presence of mRNA for IL-2 in 3/S (60%) of biopsies of rejecting grafts. An 
explanation for finding uncoated CD2S-positive cells in the presence of effective 
BTS63 plasma levels may be found in the low distribution volume of the 
monoclonal, leading to insufficient tissue concentrations. 
An important difference between the renal and heart transplant study is the fact 
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that renal transplant recipients started using cyclosporin on day 0, whereas in 
heart transplant recipients this was delayed until day 3, in order to prevent renal 
insufficiency in the immediate postoperative period. In animal studies a synergistic 
effect of combining cyclosporin and anti IL-2R mAbs has been demonstrated. 
Possibly the results of rejection-prophylaxis with 8T563 in the heart transplant 
recipients would have been different if cyclosporin had been started on day 0, 
thereby making optimal use of the synergistic effect of combining 8T563 and 
cyclosporin. 
An overview of all published randomized trials using anti IL-2R mAbs in organ 
transplantation is presented on page 105. In conclusion, the use of anti IL-2R 
MoAbs as a prophylaxis against rejection after organ transplantation is safe and 
does not lead to an increased incidence of infectious complications. Their efficacy 
in kidney transplantation is now shown by several studies' 2 3 '. In liver 
transplantation considerable differences between the results obtained with several 
different anti IL-2R mAbs have been found' '. 8T563 as a prophylaxis against 
rejection in liver transplantation was most effective'1O. In our study using anti IL-
2R mAb in human cardiac transplantation 8T563 seems equally effective in 
preventing acute rejection compared to OKT3, although rejections tend to come a 
little sooner". Combining anti IL-2R MoAbs with cyclosporin from the day of 
transplantation is most effective, as shown by stUdies in liver transplantation" 10 
and by our kidney study'. 
Allhough the observed efficacy of 8T563 in the treatment of rejection in three 
heart transplant recipients is promising, it can not be concluded that anti IL-2R 
monoclonals are effective in the treatment of established graft rejection. In solid 
organ transplantation experience with anti IL-2R monoclonals for this indication is 
limited. Resulls of treating graft-versus-host disease after bone marrow 
transplantation are inconclusive. 
Whether humanized antibodies, that are markedly less immunogenic and have 
improved pharmacokinetics with prolonged in vivo survival, have equal or even 
better efficacy and safety remains to be proven. The long half life may potentially 
lead to prolonged periods of CD25-absence and over-immunosuppression. 
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Year of 
Publication 
(Ref.) 
1990 (1) 
1991 (2) 
1993 (3) 
1994 (4) 
1995 (5) 
1994 (6) 
1991 (7) 
1993 (8) 
1993 (9) 
1995 (10) 
1996 (11) 
RANDOMIZED TRIALS OF ANTIIL-2R INDUCTION TREATMENT IN ORGAN TRANSPLANTATION 
MoAb Control Duration Combined OUTCOME 
Group of with 
Treatment 
Rejection Infections Other side Effects 
Incidence 
33B3.1 rATG 14 predJaza 33B3.1 =rA TG 33B3.1 <rATG 33B3.1<rATG 
Jater GsA 
antiTac 
-
10 triple antiTac<control antiTac=control antiTac=control 
Lo-TacH ALG 14 triple La-Tact-1 =ALG La-Tact-1 <ALG Lo-Tact-1=ALG 
33B3.1 rATG 10 pred/aza 33B3.1>rATG 3363.1 <rATG 33B3.1=rATG 
i later CsA 
BT563 placebo 10 CsA/pred BT563<placebo BT563=placebo BT563=placebo 
33B3.1 rATG 10 triple 33B3.1>rATG 33B3.1 =rATG 33B3.1=rATG 
YTH-906 placebo 10 triple YTH-906=placebo YTH-906=placebo YTH-906=placebo 
Lo-Tact-1 OKT3 10 triple La-Tact-1=OKT3 Lo-Tact-1<OKT3 Lo-Tact-1=OKT3 
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BT563 ATG 12 triple BT563<ATG BT563=ATG BT563<ATG 
BT563 OKT3 7 CsA/pred BT563=OKT3 BT563=OKT3 BT563<OKT3 
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Chapter 9 
Samenvatting en conclusies. 
9.1 Samenvatting en conclusies 
Diverse monoclonale en polycionale antilichamen werden in de afgelopen jaren 
gebruikt als inductie therapie na orgaan transplantatie. Naast de directe 
bijwerkingen gepaard gaande met hun gebruik, zoals het "cytokine release 
syndrome", resulteert de diepe immunosuppressie veroorzaakt door deze middelen 
in een toegenomen incidentie van infecties en op den duur van maligniteiten. Ter 
voorkoming van de nadelen die kleven aan het gebruik van dergelijke aspecifiek 
werkende immunosuppressiva werden monoclonale antilichamen ontwikkeld die 
gericht zijn tegen specifieke T-cel activatie antigenen. Gezien de centrale rol van 
Interleukine·2 (IL-2) bij de activatie van antigen·gestimuleerde Iymfocyten leken 
antilichamen gericht tegen de Interleukine·2 receptor (lL-2R) een goed voorbeeld 
van een krachtig immunosuppressief middel gericht tegen aileen geactiveerde 
Iymfocyten. 
In vitro studies met verschillende anti IL-2R monoclonalen lieten zien dat er 
onderlinge verschillen zijn in effectiviteit. Afhankelijk van de epitoop die wordt 
herkend, de affiniteit van het monoclonaal, het type F ,·receptor, de resulterende 
anti-muis antilichaam respons en de halfwaardetijd van het antilichaam varieert de 
in vivo werkzaamheid. Voor sommige monoclonalen geldt dat de effectiviteit in vivo 
lijkt te worden weerspiegeld in de resultaten van in vitro experimenten. Zo blijkt de 
immunosuppressieve invloed van anti·Tac in vitro, in vergelijking met die van 
33B3.1 en BT563, beperkt te zijn. BT563 bleek in concentraties die klinisch goed 
haalbaar zijn een sterke remming te geven van de proliferatie in mixed lymphocyte 
reactions. BT563 leek dan ook een goede keuze te zijn om in vivo studies bij 
niertransplantatie patienten te starten. 
Een pilot studie, waarin aan 12 niertransplantatie patienten BT563 als 
inductietherapie werd toegediend, toonde dat in perifeer bloed aile CD25 positieve 
cellen tijdens de behandeling afgedekt worden met het antilichaam en dat het 
middel geen bijwerkingen veroorzaakte. Bovendien bleek geen van aile 12 patienten 
na transplantatie een rejectie te krijgen. 
De veelbelovende resultaten van het in vitro werk en van de pilot studie waren 
aanleiding am in 1991 twee grote gerandomizeerde klinische studies te starten, 
waarbij BT563 werd toegepast ter preventie van rejectie na nier· en 
harttransplantatie. 
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Zestig eerste en tweede niertransplantaat ontvangers werden gerandomizeerd voor 
dubbel-blinde behandeling met placebo of BT563 gedurende de eerste 10 dagen na 
transplantatie. Vanaf dag 0 ontvingen aile patienten prednison and cyclosporine als 
onderhoudsmedicatie. Aan de medicatie gerelateerde bijwerkingen werden niet 
waargenomen. Tijdens de behandeling met BT563 kreeg geen enkele patient een 
afstoting, terwijl in de placebo-groep tijdens de eerste 10 dagen 7/29 patienten een 
acute rejectie hadden (p = 0.01). Vier weken na transplantatie was 96% resp. 76% 
van de patienten vrij van afstoting in de BT563 en placebo-groep (p =0.05). Als 
gevolg van rejectie gingen in de placebo-groep twee transplantaten verloren. 
Infecties waren gelijkelijk verdeeld over beide groepen. De conclusie van dit 
onderzoek luidt dat BT563 effectief is in het voorkomen van afstoting na 
niertransplantatie, zander dat dit leidt tot vervelende bijwerkingen of een 
toegenomen frequentie van infecties. 
Een tweede onderzoek werd verricht onder 60 harttransplantatie patienten, die 
werden gerandomizeerd voor behandeling met BT563 of OKT3 als rejectie-
profylaxe. Deze patienten hadden ook prednison en cyclosporine als 
onderhoudsmedicatie, maar cyclosporine werd pas gestart op dag 3 na 
transplantatie. De meeste (27/29) met OKT3 behandelde patienten ondervonden 
sen of meer verschijnselen van het "cytokine release syndrome" (koorts, 
hypotensie, verwardheid, rash). Een aantal (13/31) van de met BT563 behandelden 
had enige verwardheid of subfebriele temperatuur in de direct post-operatieve fase, 
maar dit bleek niet levensbedreigend en was niet anders dan wat ook normaliter na 
open-hart chirurgie gezien wordt. Acute rejectie werd in de BT563-groep vaak 
gezien in het eerste biopt (week 1) na transplantatie (14/29=48%), terwijl dit in 
de met OKT3 behandelde patienten veelal werd gevonden in de biopten genomen 
op week 3,4 of 5 (15/29 = 52%). Drie maanden na transplantatie was het verschil 
in afwezigheid van afstoting tussen de twee groepen niet meer aanwezig (1 7 vs 
21%). Evenmin was er een verschil tussen de twee groepen in de vanwege 
afstoting toegediende hoeveelheden corticosteroid en of in de aantallen kuren anti 
T-cel therapie (OKT3/ATG). Ook hier waren ernstige en minder ernstige infecties 
in beide groepen even frequent. 
In de harttransplantatie studie werd dus bij enkele patienten een afstoting in het 
transplantaat geconstateerd terwijl zij net de BT563 behandeling hadden ontvangen 
en er bij hen in perifeer bloed aileen door het monoclonaal afgedekte CD25 
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positieve cellen in perileer bloed aantoonbaar waren. Om te onderzoeken 01 wellicht 
in het hart wei vrije IL-2 bindingsplaatsen (onbedekt CD25) aanwezig waren werd 
immunohistochemisch onderzoek verricht op de week 1 biopten. In de 
endomyocardbiopten van 80% van de rejecterende patienten bleken onbedekte 
CD25 positieve cellen aantoonbaar te zijn, terwijl dit bij de niet rejecterende 
patienten slechts in 22% van de patienten het geval was. RT-PCR onderzoek op 
een beperkt aantal biopten toonde bovendien aanwezigheid van mRNA voor IL-2 
in 3/5 (60%) van de rejectie-biopten. Een verklaring voor het leit dat BT563 
blijkbaar wei in de circulatie maar niet in het transplantaat zell in staat was CD25 
volledig al te dekken zou gelegen kunnen zijn in het lage verdelingsvolume van het 
monoclonaal. 
De twee onderzoeken vergelijkend lijkt het zo te zijn dat BT563 bij de 
niertransplantatie patienten wei en bij de harttransplantatie patienten minder 
effectiel is. Een belangrijk verschil tussen de twee onderzoeken is dat in de nieren-
studie gestart werd met cyclosporine op dag 0, terwijl dit bij de harttransplantaties 
werd uitgesteld tot dag 3, ter voorkoming van ernstige nierlunctiestoornissen in de 
direct post-operatieve periode. In dierexperimenteel onderzoek werd een duidelijk 
synergistisch effect gevonden bij het combineren van cyclosporine en anti IL-2R 
monoclonalen. Mogelijk zouden de resultaten bij de harten-studie anders zijn 
geweest als daar ook was gestart met cyclosporine op de eerste post-operatieve 
dag. 
Een overzicht van aile tot heden gepubliceerde gerandomizeerde onderzoeken met 
anti IL-2R monoclonale antilichamen als inductie therapie na orgaantransplantatie 
wordt gegeven op pagina 114. Concluderend kan worden gesteld dat het gebruik 
van anti IL-2R monoclonalen na orgaan transplantatie veilig is en niet leidt tot een 
toename van inlecties. De effectiviteit van IL-2R monoclonalen ter preventie van 
rejectie na niertransplantatie, zoals oak gevonden door anderen 123, kan door ons6 
worden bevestigd. In de literatuur worden na levertransplantatie wisselende 
resultaten gemeld'·, maar met name BT563 lijkt hierbij het meest effectiel' '0. In 
ons onderzoek met BT563 na harttransplantatie blijkt dat dit gelijkwaardig is aan 
OKT3, olschoon de rejecties wei wat eerder na transplantatie optreden ". Op grond 
van dierexperimenteel onderzoek, onze resultaten bij de niertransplantatie patienten 
en de beschreven effecten na levertransplantatie wordt geadviseerd BT563 te 
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combineren met cyclosporine. 
Of schoon de beschreven effectiviteit van BT563 als behandeling van een 
aangetoonde rejectie na harttransplantatie veelbelovend is, kan niet worden 
geconcludeerd dat anti IL-2R monoclonalen bij allograft rejectie werkzaam zijn. 
Hiernaar is nog onvoldoende onderzoek verricht. 
Of gehumaniseerde anti IL-2R monoclonalen, die minder immunogeen zijn en 
langere halfwaardetijden hebben, dezelfde of misschien zelfs betere effectiviteit 
hebben valt te bezien. Met name de lange halfwaardetijd zou kunnen leiden tot 
overimmunosuppressie met aile gevolgen van dien. 
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RANDOMIZED TRIALS OF ANTIIL-2R INDUCTION TREATMENT IN ORGAN TRANSPLANTATION 
Organ Year of MoAb Control Duration Combined , OUTCOME 
Publication Group of with 
(Ref.) Treatment 
Rejection Infections Other side Effects 
Incidence 
kidney 1990 (1 ) 3383.1 rATG 14 pred/aza 3383.1=rATG 33B3.1 <rATG 33B3.1 <rATG 
i later CsA 
1991 (2) antiTac 
-
10 triple antiTac<control antiTac=control antiTac=control 
1993 (3) La-TacH ALG 14 triple La-Tact-1=ALG Lo-Tact-1<ALG La-Tact-1=ALG 
1994 (4) 33B3.1 rATG 10 pred/aza 3383.1>rATG 3383.1<rATG 33B3.1=rATG 
later CsA 
1995 (5) BT563 placebo 10 CsA/pred 8T563<placebo BT563=placebo BT563=placebo 
kidney 1994 (6) 33B3.1 rATG 10 triple 33B3.1 >rA TG 33B3.1 =rATG 33B3.1=rATG 
pancreas 
liver 1991 (7) YTH-906 placebo 10 triple YTH-906=placebo YTH-906=placebo YTH-906=placebo 
1993 (8) La-Tact-1 OKT3 10 triple Lo-Tact-1=OKT3 La-Tact-1 <OKT3 La-Tact-1=OKT3 
La-Tact-1 placebo 10 triple Lo~ Tact-1 <placebo La-Tact-1=placebo La-Tact-1=placebo 
1993 (9) BT563 ATG 10 triple BT563<ATG 8T563=ATG BT563=ATG 
1995 (10) BT563 ATG 12 triple BT563<ATG BT563=ATG 8T563<ATG 
heart 1996 (11) BT563 OKT3 7 CsA/pred 
, 
BT563=OKT3 8T563=OKT3 BT563<OKT3 
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